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Two posttranslational modifications, ISGylation and phosphorylation, impact the 
replication of influenza A virus, a human pathogen responsible for high mortality 
pandemics. The ubiquitin-like ISG15 protein is induced by type 1 interferon (IFN) and is 
conjugated to many cellular proteins by three enzymes that are also induced by IFN. 
Experiments using ISG15-knockout (ISG15-/-) mice established that ISG15 and/or its 
conjugation inhibits the replication of influenza A virus, but inhibition was not detected 
in mouse embryo fibroblasts in tissue culture. The present study is focused on the effect 
of ISG15 and/or its conjugation on the replication of influenza A virus in human cells in 
tissue culture. IFN-induced antiviral activity against influenza A virus in human cells was 
significantly alleviated by blocking ISG15 conjugation using small interfering RNAs 
(siRNAs) against ISG15 conjugating enzymes. IFN-induced antiviral activity against 
influenza A virus gene expression and replication was reduced 10-20-fold by suppressing 
ISG15 conjugation. Unconjugated ISG15 does not contribute to this antiviral activity. 
Consequently human tissue culture cells can be used to delineate how ISG15 conjugation 
 vii
inhibits influenza A virus replication. SiRNA knockdowns were also used to demonstrate 
that other IFN-induced proteins, specifically p56, MxA and phospholipid scramblase 1, 
also inhibit influenza A virus gene expression in human cells. The research on 
phosphorylation focused on the viral NS1A protein, a multifunctional virulence factor. 
Although threonine phosphorylation of the NS1A protein was discovered 30 years ago, 
the sites of phosphorylation and its function had not been identified. A recombinant 
influenza A virus encoding an epitope-tagged NS1A protein was generated, enabling the 
purification of NS1A protein from infected cell extracts. Mass spectrometry identified 
phosphorylation at T49 and T215. A recombinant virus in which phosphorylation at 215 
was abolished by replacing T with A is attenuated, and an apparently aberrant NS1A 
protein is produced. Attenuation did not occur when T was changed to E to mimic a 
constitutively phosphorylated state, or surprisingly when T was changed to P to mimic 
avian NS1A proteins. These results suggest that T215 phosphorylation in human viruses 
and P215 in avian viruses can support analogous functions. 
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Chapter 1 : Literature Review 
 
1.1 INFLUENZA VIRUS 
1.1.1 Overview 
Influenza A viruses are important respiratory pathogens which cause significant 
mortality and morbidity throughout the world every year. Among the three major human 
pandemics occurred last century, the “Spanish flu” in 1918 was the most deadly one and 
cost more than 30 million lives. The other two, “Asian flu” in 1957 and “Hong Kong flu” 
in 1968, also resulted in significant mortality rate. Pandemic influenza viruses usually 
result from gene reassortments between different strains, a process called “antigenic 
shift”.  The reassortants encode proteins which are distinct from the previous circulating 
strains, and as a result, there is little immunological protection against these new viruses 
in human populations. The recently isolated highly virulent avian influenza H5N1/1997 
and H5N1/2004 have led to the speculation of the emergence of new pandemic outbreak. 
Most H5N1 viral infections had been limited to avian-to-human transmissions. These 
infections caused severe respiratory symptoms in infected human patients and resulted in 
high mortality rate. If the H5N1 virus acquires the ability of efficient human-to-human 
transmission by gene reassortments and/or mutations, it would be expected to cause the 
next human pandemic and possibly claim millions of lives. 
Influenza A virus is a member of the Orthomyxoviridae family, which also 
includes 3 other genera: influenza virus B, influenza virus C, and Thogotovirus, 
distinguished by the antigenic differences between their nucleoproteins (NP) and matrix 
proteins (M1). These viruses are enveloped single-stranded (-)RNA viruses with a 
segmented genome. Both influenza A and B viruses contain eight genomic RNA 
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segments, whereas influenza C contains only seven genomic RNA segments. Influenza A 
virus is responsible for the most severe influenza pandemics in the past and has a broad 
host range including humans, pigs, horses, whales, seals, and birds. Influenza B and C 
viruses infect mainly humans (Lamb and Krug 2001).  
Influenza A viruses can be further divided into different subtypes based on the 
antigenic variation of the surface glycoproteins, hemagglutinin (HA) and neuraminidase 
(NA). Currently there are 16 known subtypes of HA (H1-H16) and 9 known subtypes of 
NA (N1-N9). While all subtypes can be found in wild aquatic birds, since they are the 
natural hosts of influenza viruses, only H1N1, H2N2, H3N2, H5N1, H7N7, and H9N2 
subtypes have been isolated from human. Among them, three HA subtypes, H1, H2, H3, 
and two NA subtypes, N1 and N2, have caused human epidemics (Julkunen et al. 2001).  
 
1.1.2 Structure of influenza A virus  
The influenza A virus contains a bilayer phospholipid envelope derived from the 
host cell membrane during the viral budding process (Lamb and Krug 2001). Three viral 
proteins, HA, NA, and M2, which are embedded in the lipid envelope, are encoded by 
segments 4, 6, and 7, respectively. The HA and NA proteins are anchored in the envelope 
by short sequences of hydrophobic amino acids and form the spike-shaped outer layer 
(Figure 1.1). The HA protein is a homotrimer, and is responsible for binding to the sialic 
acid-containing receptors on the cell surface and for subsequent membrane fusion that 
releases the internal components into the cell. The NA protein, which forms a 
homotetramer, destroys receptors by hydrolyzing sialic acid from glycoproteins and 
facilitates the release of viral progeny. The M2 protein is an integral membrane 
homotetramer, which functions as an ion channel by pumping hydrogen ions (H+) into 
the virus particle, which is essential for virus uncoating and the later migration of viral 
 3
 
Figure 1.1 Schematic diagram of the structure of influenza A virion. The location 
of the structural viral proteins, viral envelope, and the eight genomic RNA 
segments are indicated. The NS1A and PB1-F2 are found only in infected 
cells, and not in virions. Modified from Noah and Krug 2005. 
(nuclear export protein) 
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core ribonucleoprotein complex (RNPs) into the nucleus. Under the lipid envelope lays a 
layer of M1 protein, which is also encoded by segment 7 that gives rise to M2 protein as 
a result of alternative splicing. M1 is the most abundant protein in the viral particle with 
important structural roles and regulatory functions associated with RNPs. M1 mediates 
the encapsidation of the viral ribonucleoprotein complexes into the viral envelope. Inside 
the virion, all eight viral RNA segments are bound to the NP and the viral RNA 
polymerase to form ribonucleoprotein(RNP) complexes (Figure 1.2). The heterotrimeric 
RNA polymerase complex contains 3 subunits: PB2, PB1 and PA, which are encoded by 
the three largest vRNA segments, segment 1, 2, and 3 respectively. The NP protein, 
encoded by segment 5, is a non-specific single stranded RNA (ssRNA) binding protein, 
and each NP monomer interacts with approximately 20 nucleotide of the vRNA. Both 
ends of the vRNA interact with each other to form a supercoil structure, and the RNA 
polymerases interact with both ends of the vRNA within the virion. The three 
polymerases and NP proteins are the minimum combination which is required for 
influenza virus genome replication and RNA transcription. The NS2A protein (Mr  
~14,000), encoded by segment 8 by alternative splicing with +1 frameshift of its ORF 
compared to NS1A, is also present in virions in low amounts associated with the M1 
protein and functions as a nuclear export protein for vRNP in infected cells (NS2/NEP). 
The eight segments of influenza A virus genome encodes 10, or 11, proteins. Viral 
mRNAs from segment 1 through 6 are basically monocistronic. However, the viral 
mRNA encoded by segment 2 of some viruses contains a short alternative reading frame 
that encodes the PB1-F2 protein which has a role in apoptosis. Viral mRNAs from 
segments 7 and 8 undergo alternative splicing and thus encode two proteins. Among all 
the proteins encoded by influenza A virus genome, only the NS1 protein from segment 8, 
and, in some cases, the PB1-F2 protein from segment 2, are non-structural proteins. 
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Figure 1.2 Model of the influenza virus RNP structure.  Blue spheres represent NP 
monomers with associated vRNA molecule (black line). The single-stranded 
vRNA is coiled into a hairpin structure with a short region of duplex 
(formed between the 5´ and the 3´ ends) which forms the binding site for the 
heterotrimeric RNA-dependent RNA polymerase. Adapted from Portela and 
Digard 2002. http://wwwmicro.msb.le.ac.uk/3035/Orthomyxoviruses.html 
NP 
Polymerase 
subunits 
(-) sense 
ssRNA
Influenza virus RNP 
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1.1.3 Replication of influenza A viruses 
Influenza viruses enter cells by binding to sialic acid residues present on cell 
surface glycoproteins or glycolipids via the receptor-binding site in the distal tip of the 
HA molecules, and are engulfed in endosomes, a process called “receptor-mediated 
endocytosis”. Following internalization and fusion with endosomes, RNP complexes are 
dissociated from M1 proteins and liberated to the cytoplasm mediated by acidic pH 
changes in the endosome. RNPs then enter the nucleus through the nuclear pore (Martin 
and Helenius 1991). The transcription and replication for influenza virus genome occur in 
the nucleus of infected cells. The viral RNAs (vRNAs) are transcribed into viral mRNAs 
and replicated by the viral polymerase complex. The genome of influenza virus is 
negative-stranded RNA. vRNAs are templates for the synthesis of both mRNAs and 
cRNAs. cRNA is the exact complimentary copy of vRNA and acts as a template for 
further synthesis of vRNA. All eight vRNA segments contain 12 and 13 conserved 
nucleotides at their 3’ and 5’ ends, respectively. In addition, each RNA segment also 
contains 2 to 3 segment specific nucleotides near each end. These RNA sequences are 
partially complementary and can form a panhandle structure. Viral mRNA is a capped 
and polyadenylated transcript. It is an incomplete copy of the vRNA, lacking 
approximately 17 bases of the complementary viral 3’ sequence. Unlike vRNA and 
mRNAs, cRNAs are not transported to the cytoplasm during viral infection. At the end of 
the infection cycle, the newly assembled RNPs are exported into the cytoplasm and 
incorporated into progeny virions, which are released from the cell surface through 
budding (Fig 1.3)(Lamb and Krug 2001).  
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Figure 1.3 Schematic diagram of the life cycle of influenza A virus. Influenza A 
virus binds to the cell surface and enters the cell by receptor-mediated 
endocytosis. Following internalization and fusion with the endosome, viral 
RNPs are released in the cytoplasm. Viral RNPs enter the nucleus through 
the nuclear pore. In the nucleus of infected cells, the viral RNAs are 
transcribed into mRNAs and replicated by viral polymerase complexes. The 
newly assembled viral RNPs are exported into the cytoplasm and 
incorporated into mature virions which are released from the cell surface by 
budding. Adapted from Lamb and Krug 2001. 
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The syntheses of influenza viral mRNAs are initiated by the unique “cap-
snatching” mechanism (Figure 1.4). The PB2 subunit of viral polymerase binds to the 5’ 
end of host cell mRNA and cleaves capped (m7GpppNm-containing) cellular RNA 10-13 
nucleotides downstream from the 5’end via its cap-dependent endonuclease activity. 
After cleavage, the short-capped RNA fragment subsequently serves as a primer for 
initiation of viral mRNA synthesis by the viral polymerase (Plotch et al. 1981). The cap 
structure (m7GpppNm) from mammalian cellular mRNA is the preferred primer for viral 
transcription. Although the viral mRNAs also contain the capped structure, they seem to 
be protected from the endonucleolytic cleavage. These observations suggested that the 
viral polymerase complex selectively uses host mRNA for viral mRNA synthesis (Shih 
and Krug 1996). The viral polymerase complex elongates viral mRNA until reaching a 
stretch of 5 to 7 uridine(U) residues located 15-22 nucleotides before the 5’ end of 
the‘vRNA template. After reiteratively copying the U-track at the 5 ‘end of vRNA 
template, the viral polymerase generates the 3’ polyadenylated tail for the viral mRNAs 
in a host-independent process (Plotch et al. 1979; Poon 1999). 
The viral polymerase is also responsible for the replication of vRNAs in the 
nucleus (Krug et al. 1989). The replication of vRNAs occurs in two steps: (1) the 
synthesis of full-length complementary RNAs (cRNAs) by using vRNAs as templates; 
and (2) the synthesis of full-length progeny vRNAs by copying cRNAs. Unlike viral 
mRNA synthesis, the synthesis of cRNAs and vRNAs is initiated de novo without a 
primer (unprimed initiation), and is not terminated at the poly (A) site (antitermination). 
It has not been determined what triggers the switch of influenza viral polymerase activity 
from capped RNA-primed transcription to unprimed viral RNA replication. However, the 
free NP proteins not associated with nucleocapsids are required for the specific 
encapsidation of vRNAs and cRNAs but not mRNAs. Furthermore, the function 
 9
 
Figure 1.4 “Cap-snatching” by the influenza viral polymerase. See text for details. 
Adapted from Chen and Krug 2000. 
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of free NP protein is required for: 1) antitermination at poly (U) stretch as part of the 
switch from mRNA to full-length cRNA synthesis (Beaton and Krug 1986), and 2) 
synthesis of vRNAs from cRNA templates (Shapiro and Krug 1988). 
Viral gene expression in influenza A virus infected cells is regulated over the time 
course of infection. In general, the amount of viral proteins synthesized in infected cells 
is largely dependent on the amount of the corresponding mRNA in infected cells. Primary 
transcription occurs immediately after infection. During this stage, all eight viral mRNAs 
are synthesized in equimolar amounts, and the synthesis of vRNAs, viral mRNAs, and 
viral proteins are coupled. Second transcription stage occurs subsequently and can be 
further divided into early and late phases (Shapiro et al. 1987; Shapiro and Krug 1988). 
In the early phase, the synthesis rates of both viral mRNA and vRNA increase 
simultaneously; the late phase is defined by the decrease in the rate of viral mRNAs 
synthesis while the synthesis of all vRNAs still remain at or near the maximum during 
this entire period (Shapiro and Krug 1988). Also, in the early phase of the secondary 
transcription, NS1 and NP vRNA are preferentially synthesized. As a consequence, NS1 
and NP are the predominant viral proteins in infected cells at this stage. The reason for 
the preferential early expression of the NS1 and NP proteins might be that NP is required 
for the replication and transcription of viral RNA and NS1 is required for the regulation 
of cellular gene expression. During the late phase, vRNAs are synthesized in equivalent 
amounts, as required for progeny virus genome. At this stage, the NS1 protein is 
synthesized in a reduced level, but HA, NA, and M1 mRNAs are preferentially 
expressed. Capped and polyadenylated viral mRNAs are transported from the nucleus to 
the cytoplasm for protein synthesis. The membrane-bound proteins, such as HA, NA, and 
M2, are post-translationally glycosylated in the trans-Golgi network (Figure 1.3), and are 
transported to the cell surface for incorporation into the cell membrane.  
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1.1.4 NS1 protein of influenza A virus (NS1A protein)  
The non-structural NS1 protein of influenza A virus (NS1A) is a multifunctional 
protein that participates in protein-RNA and protein-protein interactions (Krug et al. 
2003). The NS1A protein, and also the NS2A protein, is encoded by the smallest 
genomic RNA segment 8, which contains ≈ 890 nucleotides (Lamb and Choppin 1979). 
The NS1A protein is encoded by the collinear mRNA transcript, whereas a spliced 
mRNA (NS2A mRNA) encodes the NS2A protein. The NS1A and NS2A proteins share 
the same 10 amino acids at their N-terminus (Fig 1.5). Subsequent amino acids differ 
because the NS2A reading frame after the 3’ splice site is +1 relative to that of NS1A. 
Splicing is inefficient, resulting in a 10:1 ratio of unspliced NS1A mRNA: NS2 spliced 
mRNA, and the proteins are synthesized in the same relative amounts The NS1A protein, 
approximately 26kDa, contains 202 to 237 amino acids among different influenza A virus 
strains. It is designated as a “nonstructural” protein because it is synthesized in large 
amounts in infected cell, but not incorporated into virions (Lazarowitz et al. 1971).  
The NS1A protein is composed of two functional domains (Qian et al.1994): the 
N-terminal first 73 amino acids form the RNA-binding domain (RBD) of a symmetric 
homodimer with a unique six-helical chain fold (Liu et al. 1997; Chien et al. 1997; Yin et 
al. 2007); and the remaining two-thirds carboxyl terminus forms the effector domain . As 
determined by both nuclear magnetic resonance (NMR) and X-ray crystallography, 
NS1A RBD forms a symmetrical homodimer with a unique six-helical chain fold (Figure 
1.6A), which differs from that of the predominant class of dsRNA-binding domains that 
are found in a large number of cellular proteins (Qian et al. 1995; Chien et al. 1997; Liu 
et al. 1997; Wang et al. 1999; Yin et al. 2007). 
 12
 
 
  
 
 
Figure 1.5 Alternative splicing of the NS2 mRNA. The NS1A protein is encoded by 
the collinear mRNA transcript, whereas a spliced mRNA (NS2 mRNA) 
encodes the NS2A protein. The NS1A and NS2A proteins share the same 10 
amino acids at their N-terminus Subsequent amino acids differ because the 
NS2A reading frame after the 3’ splice site is +1 relative to that of NS1A. 
  
 
NS gene 
NS1 mRNA 
NS2 mRNA 
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Figure 1.6 Models of the RNA-binding domain of NS1A protein. (A) The three-
dimensional structure of RNA-binding domain of the NS1A protein. Amino 
acids R38, R38’, K41, and K41’ that are crucial for RNA binding are shown 
as indicated. (B) Model of the RNA binding groove for the RBD dimer. 
(A) 
(B) 
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According to the gel filtration and sedimentation equilibrium measurements, the 
dimer of NS1A RBD binds to the 16 base-pair synthetic dsRNA duplex with an apparent 
dissociation constant (Kd) of approximately 1 μM. By comparison, the predominant class 
of cellular dsRNA-binding proteins containing one or more dsRBMs has approximately 
5,000-fold higher affinity for dsRNA (Tian and Mathews 2001). Although the NS1A 
RBD binds dsRNA with low affinity, it already accounts for all of the dsRNA binding 
activities of the full-length protein (Qian et al. 1995). 
Each polypeptide chain of the NS1A RNA-binding domain consists of three α-
helices: Helix1, residues Asn4-Asp24; Helix 2, Pro31-Leu50; and Helix 3, Ile54-Lys 70 
(Wang et al. 1999; Chien et al. 2004). The symmetrical homodimer structure is required 
for dsRNA binding, and the antiparallel helices 2 and 2' play a central role in binding the 
dsRNA target. The arginine side chain at position 38 (R38) in the second α-helix is the 
only amino-acid side chain that is absolutely required for dsRNA binding, and the lysine 
side chain at position 41 (K41) also contribute to the binding affinity (Wang et al. 1999). 
Furthermore, NS1A RBD binds to canonical A-form dsRNA, but does not bind to 
dsDNA or dsRNA-DNA hybrids, which feature B-type or A/B-type intermediate 
conformations, respectively (Chien et al. 2004). The current hypothetical model is that 
NS1A RBD sits astride the minor groove of A-form RNA with a few amino acids in the 
helix 2-helix 2' face forming an electrostatically stabilized interaction with the 
phosphodiester backbone (Figure 1.6(B)). This mode of dsRNA binding differs from that 
observed for any other dsRNA-binding protein. Although NS1A RBD also binds in vitro 
to a specific stem-bulge of U6 snRNA (Qiu and Krug 1994; Qiu et al. 1995), and binds 
with a lower affinity to a specific stem-bulge in the minor U6 atac snRNA (Wang and 
Krug 1998), no biological role of this binding has been found. 
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The primary function of the NS1A RNA-binding domain has been elucidated. 
Early studies suggested that the NS1A RNA-binding domain acts by sequestering viral 
dsRNA away from, and inhibit the activation of, the endogenous cellular PKR kinase 
(Nemeroff et al. 1995; Lu et al. 1995). Research conducted in our laboratory using a 
recombinant influenza A/Udorn/72 virus expressing a NS1A protein lacking dsRNA-
binding activity, i.e., a virus encoding a NS1A protein with a R38A amino acid 
substitution, clarified two controversial aspects of the functions of this domain. First, 
NS1A protein inhibits the activation of PKR, not by sequestering dsRNA, but by direct 
binding via its effector domain to the N-terminal region of PKR (Li et al. 2006; Min et al. 
2007). Second, the dsRNA-binding activity of NS1A protein does not have a role in 
inhibiting the influenza A virus-induced synthesis of IFN-β mRNA. Rather, the primary 
function of the NS1A dsRNA-binding activity is to protect influenza A virus against the 
antiviral state induced by IFN-beta by inhibiting the IFN-α/β-induced 2'-5'-oligo (A) 
synthetase (OAS)/RNase L pathway (Min and Krug 2006).  
The C-terminus of the NS1A protein forms the effector domain, extending from 
the end of the RNA-binding domain to the carboxyl terminal amino acid (Qian et al. 
1994; Chen and Krug 2000). NS1A effector domain forms dimers (Bornholdt and Prasad 
2006; Hale et al. 2008) (Figure 1.7). Each monomer consists of seven β-strands and three 
α-helices. Six of the β-strands form an antiparallel β-sheet, but not the last one. The β-
sheet surrounds the long α-helix, which is held in the central through hydrophobic 
interactions between the β-sheet and the α-helix. This structure is described as a “α-helix 
β-crescent fold”. Different models have been proposed for the formation of the effector 
domain dimer. In Prasad’s model (Figure 1.7(B)), the interface of the effector domain 
dimer, PR8/NS1Δ72, is formed by the first N-terminal β-strand of each monomer (strand-
strand dimer). These β-strands run antiparallel to each other along the dimeric interface.  
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Figure 1.7 Models of the dimeric structure of NS1A effector domain.  (A) Helix-
to-helix dimer. Hale’s model. The interface of the effector domain dimer , 
NS1A, Alb/ NS1Δ72, is between the two long α-helices of the monomers, 
and Trp-187 is essential for the dimerization. (B) Strand-to-strand dimer. 
Prasad’s model. The interface of the effector domain dimer, PR8/NS1Δ72, is 
formed by the first N-terminal β-strand of each monomer (strand-strand 
dimer). These β-strands run antiparallel to each other along the dimeric 
interface. 
(A) (B) 
Trp-187 
Trp-187 
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 In contrast, in Hale’s model (Figure 1.7(A)) the effector domain dimer of an 
avian influenza virus NS1A, Alb/ NS1Δ72, shows the interaction between the two long α-
helices of the monomers, and Trp-187 is essential for the dimerization. There are still 
possibilities that there are functional roles for both dimeric states, which occur in either a 
strain-specific or ligand-dependent manner. Thus, NS1A proteins may exhibit variation in 
their dimeric assemblies, a property that could contribute to their apparent 
multifunctional nature. It should also be noted that dimerization of the isolated NS1A 
protein effector domain may differ from that observed in the full-length NS1A protein, 
whose overall conformation is influenced by both the RNA binding and effector domains 
(Nemeroff et al. 1995).  
Because of the intrinsic protein disorder of the C-terminal “tail” residues 
downstream of Ala-202 or Asn-207, this “tail” region was not resolved in either Hale’s or 
Prasad’s models. The structure and functions of this region of NS1A are intriguing. 
Previously NS1A proteins have been described that they either lack up to ~20 residues of 
this “tail”, or have a 7 amino-acid extension (Suarez and Perdue 1998). In addition, 
several functions have been assigned to this region in avian NS1A proteins but not in 
human NS1A proteins. For example, avian NS1A proteins contain a consensus Src 
homology 3 (SH3) domain-binding motif at residues 212–215, which can interact with 
human Crk/CrkL proteins to enhance cellular PI3K activation (Heikkinen et al. 2008). In 
addition, as described in the following chapters, the Thr at 215 in human NS1A proteins 
is phosphorylated during infection, and this phosphorylation is required for optimal virus 
replication. Furthermore, the four C-terminal residues of most avian NS1A proteins form 
a putative PDZ domain ligand (Obenauer et al. 2006), and these residues of NS1A 
modulate virus pathogenicity in mice (Jackson et al. 2008).  
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The effector domains has binding sites for several cellular proteins that mediate 
various functions (Fig 1.8): (i) the inhibition of the cellular pre-mRNA 3’- end processing 
machinery by binding to the 30-kDa subunit of the cleavage and polyadenylation 
specificity factor (CPSF30) and poly(A)-binding protein II (PABII) (Nemeroff et al. 
1998; Chen et al. 1999; Li et al. 2001; Noah et al. 2003; Twu et al. 2006; ); (ii) inhibition 
of the activation of dsRNA-activated protein kinase (PKR) by direct binding of PKR(Li 
et al. 2006; Min et al. 2007); and (iii) the activation of phosphatidylinositol-3-kinase 
(PI3K) signaling by binding to p85β subunit of PI3K (Hale et al. 2006; Shin et al. 2007a; 
Ehrhardt et al. 2007).  
A major function of the NS1A protein probably is the inhibition of the antiviral 
effects of interferon (IFN). The NS1A protein inhibits the production of mature cellular 
mRNAs, including IFN-β mRNA, through its effector domain, by binding to two cellular 
proteins that are essential for the 3’end processing of cellular pre-mRNAs: the 30kD 
subunit of CPSF (Nemeroff et al. 1998) and PABII (Chen et al. 1999). The interactions 
were discovered by yeast two-hybrid screening, and the binding sites of these two 
proteins on NS1A, determined by GST-pulldown experiments, do not overlap each other: 
CPSF 30kD subunit binds to the region with amino acid 186 as the center; PABII binds to 
the region from amino acid 223 to 237 (Li et al. 2001). In the 3’ end pre-mRNA 
processing machinery, the CPSF factor recognizes and binds to the AAUAAA poly (A) 
signal, which is required for both cleavage and polyadenylation of cellular pre-mRNAs 
(Colgan and Manley 1997), and PABII stimulates the synthesis of poly (A) tails for 
cellular mRNA catalyzed by poly (A) polymerase (PAP) (Chen et al. 1999). Binding of 
NS1A protein to the CPSF 30kD subunit and PABII prevents their functions and results  
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Figure 1.8 Schematic diagram of NS1A protein structure. Binding sites of the 
cellular proteins on the NS1A effector domain are shown as indicated. 
Inhibit the IFN-α/β-induced 2'-
5'-oligo (A) synthetase 
(OAS)/RNase L pathway 
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in the accumulation of cellular pre-mRNA containing short poly (A) tails of 
approximately 12 nulceotides in the nucleus of infected cells (Nemeroff et al. 1998), 
where they would be more accessible to the viral cap-dependent endonuclease for the 
production of the capped RNA primers needed for viral mRNA synthesis (Krug 1989). 
(Figure1.9). The poly(A) tails of viral mRNAs are added by the influenza viral 
polymerase, so the inhibition of the cellular 3’end processing machinery by NS1A 
protein does not affect the production of mature viral mRNA (Poon et al. 1999). It has 
also been shown that, in vitro, NS1A protein inhibits the splicing of cellular pre-mRNAs 
by binding to a specific stem-bulge of U6 snRNA which is an important factor in pre-
mRNA splicing (Qiu et al. 1995). However, whether such inhibition also occurs in 
infected cells has not been established, since all of the sequestered cellular pre-mRNAs in 
the nucleus eventually would be degraded rapidly (Katze and Krug 1984). The inhibition 
of 3’end processing is crucial, since influenza A virus can activate the RIG-I RNA 
helicase to trigger the activation of IRF-3 and NF-κB and hence the synthesis of IFN-β 
pre-mRNA (Siren et al. 2006). 
The NS1A protein also inhibits the activation of Ser/Thr protein kinase, PKR, 
during virus infection. PKR is activated by binding to either dsRNA or the cellular PACT 
protein. Activated PKR phosphorylates the translation initiation factor eIF2α, thereby 
inhibiting viral and cellular protein synthesis and virus replication (Sadler and Williams 
2008; Sarkar and Sen 2004). As described above, instead of competing for the dsRNA 
binding, the NS1A protein directly binds to PKR and inhibits its activation mediated by 
either PACT or dsRNA. The interaction region has been determined by GST pull-down 
experiments: amino acids 123-127 of the NS1A protein interact with the N-terminal 170-
230 amino acid region of PKR. (Tan and Katze 1998; Li et al. 2006; Min et al. 2007). By 
using a recombinant influenza A/udorn/72 virus encoding a NS1A protein in which  
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Figure1.9 Mechanisms by which NS1A inhibits the cellular 3’end processing 
system in influenza-virus-infected cells. Pathway I: The binding of the 
NS1 protein to the 30kDa subunit of CPSF blocks the CPSF binding to the 
AAUAAA sequence of some cellular pre-mRNA molecules, thereby 
blocking 3’ cleavage pre-mRNAs. The uncleaved pre-mRNAs remain in the 
nucleus. Pathway II: CPSF binds to the AAUAAA sequence of other 
cellular pre-mRNA molecules, despite the binding of the NS1A protein to 
the 30kDa CPSF subunit. A short poly(A) sequence is then added to these 
cleaved pre-mRNAs by PAP in a CPSF-dependent reaction. Subsequent 
elongation of the short poly(A) sequence is blocked by the binding of the 
NS1A protein to the PABII protein, resulting in the nuclear accumulation of 
cleaved pre-mRNAs containing short poly(A) tail. The newly synthesized 
pre-mRNAs sequestered in the nucleus are cleaved by the viral cap-
dependent endonuclease to produce the primers required for viral mRNAs 
synthesis. The 3’ poly(A) sequence on viral mRNAs is produced by the viral 
polymerases and the poly(A)-containing viral mRNAs are exported from the 
nucleus. Adapted from Chen and Krug 2000. 
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amino acids 123 and 124 were changed to alanines (123/124 AA), PKR is not activated in 
vivo. The NS1A protein has been reported to interact with eIF4GI, the large subunit of 
the cap-binding complex eIF4F, and poly(A) binding protein I (PABP1)(Aragon et al. 
2000; Burgui et al. 2003), and to recruit them specifically to the 5’ UTR of viral mRNAs, 
resulting in the preferential translation of influenza viral mRNAs. However, this 
observation has not been verified by others.  
It has also been suggested that the NS1A protein interacts with the viral 
polymerase. It was reported that the three subunits of the influenza virus polymerase and 
NP can be co-immunoprecipitated with NS1A by anti-NS1A serum (Marion et al. 1997), 
This co-immunoprecipitation was insensitive to RNase treatment, indicating that the 
NS1A-polymerase interaction was not mediated by RNA, but resulted from a direct 
protein-protein interaction. One of my goals was to devise a better strategy to establish 
whether a NS1A-polymerase interaction occurs in infected cells (Chapter 3). 
The effector domain of NS1A proteins contains SH3-binding motifs, which 
mediate binding to cellular proteins. The NS1A class I SH3 binding motif (amino acids 
164-167), which is found in human and avian NS1A proteins, binds the p85β subunit of 
phosphoinositide 3-kinase (PI3K), resulting in the the PI3K-dependent phosphorylation 
of Akt (protein kinase B) (Shin et al. 2007; Hale et al. 2008; Li et al. 2008). The class II 
SH3 motif (amino acids 211-216) of NS1A protein, which is very common among avian 
strains but rarely found in human strains, binds to the adapter protein Crk/CrkL 
(Heikkinen et al. 2008). .This binding apparently enhances PI3K/Akt activation in avian 
influenza A virus infected cells. Activation of the PI3K/Akt pathway induces 
phosphorylation of caspase-9 and thereby inhibits viral-induced apoptosis, resulting in 
efficient virus replication (Ehrhardt et al. 2007; Shin et al. 2007). However, it is also 
know that NS1A protein induces apoptosis in various cells, and that caspase-3 activation 
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is important for efficient virus replication (Wurzer et al. 2003) as apoptosis promotes 
caspase-dependent migration of virus RNP complexes to the cytoplasm for efficient 
packaging into progeny virions. It is not surprising that influenza viruses have evolved to 
take advantage of existing complementary host cell responses to support their 
propagation. The mechanism which causes NS1A to switch from anti-apoptotic effects at 
early times of infection to pro-apoptotic effects later in infection remains to be elucidated.  
In addition to the important interacting partner described above, by employing 
yeast 2-hybrid system, three other cellular proteins were also shown to interact with 
NS1A:  NS1-I, a human homolog of the porcine 17β−estradiol dehydrogenase precursor 
protein (Wolff et al. 1996); NS1-BP, a human 70-kDa protein (Wolff et al. 1998), and 
hStaufen, a human homologue of Drosophila melanogaster Staufen protein (Falcon et al. 
1999). These interactions were confirmed by either GST-pull down assay, co-localization 
in cells, or co-immunoprecipitation, but they have not been shown to play a functional 
role in influenza A virus-infected cells.  
Although the NS1A protein is a relatively small protein with a molecular weight 
of approximately 26kDa, it has been reported to bind to a number of very different host 
factors and function through various pathways to support viral propagation. In addition to 
basic protein-protein interaction, there could be other biological activities involved in 
regulating the functions of NS1A, for example, phosphorylation, as described below. 
 
1.1.5 NS1A phosphorylation  
Multifunctional proteins are often regulated by post-translational modifications 
(PTMs). Advances in mass spectrometry analysis have allowed the systematic screening 
of various PTMs on proteins (Witze et al. 2007). About one-third of eukaryotic proteins 
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are phosphorylated, and protein phosphorylation has been implicated to regulate a wide 
variety of cellular processes. Numerous viral proteins have been reported to be 
phosphorylated. Phosphorylation of viral proteins has been shown to regulate different 
aspects of the virus life cycle, e.g., activation of transcription, change of cellular sub-
localization, change of protein-protein interactions, or change of protein stability (Lenard 
1999; Jakubiec and Jupin 2007). 
In addition to its RNA- and protein-binding activities, the NS1A protein is 
phosphorylated during infection (Privalsky and Penhoet 1978; Privalsky and Penhoet 
1981; Petri et al. 1982; Skorko et al. 1991). Other influenza A virus phosphoproteins 
include NP, NS2, M1, PA, and M2 (Privalsky and Penhoet 1977; Gregoriades et al. 1984; 
Skorko et al. 1991; Richardson and Akkina 1991; Holsinger et al. 1995; Arrese and  
Portela 1996; Sanz-Ezquerro et al. 1998; Thomas et al. 1998; Reinhardt and Wolff 2000; 
Huarte et al. 2003; Wu and Pekosz 2007). The phosphorylation state of NP and M1 is 
known to control their intracellular distribution (Neumann et al. 1997; Whittaker et al. 
1995). The functional association between M1 and NP is also suggested to be regulated 
by phosphorylation. Meanwhile, the role of NS1A phosphorylation during virus infection 
is not known.  
NS1A phosphorylation was first described 30 years ago (Privalsky and Penhoet 
1978). It was demonstrated by pulse-labeling infected cells with 32P-orthophosphate, and 
two-dimensional gel electrophoresis of labeled proteins. Two phosphorylated species of 
the NS1A protein were found. One species was phosphorylated at one site, and the other 
one contained two phosphorylation events. Thin-layer electrophoresis analysis of 
phosphoaminoacids established that NS1A was phosphorylated at two threonine residues 
(Privalsky and Penhoet 1981). NS1A phosphorylation is strain-specific and was not 
detected in avian NS1A proteins (Petri et al. 1982). NS1A phosphorylation is resistant to 
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bacterial alkaline phosphatase treatment. It is believed that phosphate in the intact NS1A 
protein is in the form of terminal phosphomonoesters which are protected from enzymatic 
hydrolysis. Neither the exact residues that are phosphorylated nor the role of this 
posttranslational modification in influenza virus replication has yet been determined. 
 
1.1.6 Phosphorylation of other viral proteins 
Phosphorylation is a major post-translational protein modification event and plays 
an important role in regulating multiple cellular processes. Phosphorylation could affect 
proteins by modulating their enzymatic activity, stability, cellular localization or 
interactions with other proteins.  
It has been reported that several viral proteins are phosphoproteins. The P protein 
of vesicular stomatitis virus (VSV) and the NS5A nonstructural protein of hepatitis C 
virus (HCV) are two widely studied examples. The primary phosphorylation of P protein 
occurs between residues 35 and 78. This phosphorylation of P protein is essential for the 
activation of transcription. Caesin kinase 2 (CK II) is the major cell kinase for VSV P 
protein phosphorylation and is responsible for the constitutive primary phosphorylation. 
The primary phosphorylation of P protein by CK II is necessary and sufficient for 
transcriptional activation by promoting the formation of a P protein homotrimer, which 
enables the P protein to associate with L protein and bind it to the nucleocapsid-
associated RNA template. The sites of secondary phosphorylation on P protein locate 
within residues 212-244 near the C-terminus of the P protein. The kinase that is involved 
and the functions of secondary phosphorylation are not clear. It has been proposed that 
secondary phosphorylation of VSV P protein might shut off viral replication prior to 
assembly of progeny viruses (Lenard 1999). NS5A protein of hepatitis C virus is a 
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multifunctional phosphorylated nonstructural protein involved in regulating viral 
replication and virus assembly. NS5A is phosphorylated on multiple serine and threonine 
residues. It exists as two phosphorylated forms, basally phosphorylated (p56) and 
hyperphosphorylated (p58) proteins. The basally phosphorylated form is a pre-requisition 
for establishing the hyperphosphorylated state. NS5A phosphorylation is an important 
regulatory mechanism for the viral RNA replication. Reduction of hyperphosphorylated 
form of NS5A correlates with enhanced replication of an HCV replication in tissue 
culture. It has been suggested that this effect is due to the disruption of interaction with 
the docking protein hVAP-A (human vesicle-associated membrane protein-associated 
protein A), which impairs the assembly of viral replication complexes. A critical ratio 
between the p56 and p58 phosphoforms of NS5A is required for productive HCV RNA 
replication (Huang et al. 2007). Furthermore, a recent report indicates that serine 457 of 
NS5A is a CK II phosphorylation site and phosphorylation at this site is required for 
infectious virus production (Tellinghuisen et al. 2008). 
 
1.2 CELLULAR ANTIVIRAL RESPONSE 
Host cells launch immune responses to counteract various invasions of pathogens. 
The immune responses include an early non-specific innate mechanism and a specific 
adaptive mechanism. Innate immune response is the first line of defense against viral 
infection. 
1.2.1 IFN-independent early antiviral response  
During the initial viral infection, a number of antiviral genes are induced by 
activating transcription factors controlling their expressions. This early antiviral response 
occurs prior to the production of interferons and does not require viral protein synthesis 
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(Boyle et al. 1999; Chin and Cresswell 2001; Navarro et al. 1998; Preston et al. 2001; 
Wathelet et al. 1998; Weaver et al. 1998; Yoneyama et al.1998; Parekh and Maniatis 
1999; Hiscott et al. 1999; Au et al. 1995; Kim et al. 2002; Noah et al. 2003). Upon virus 
infection, two transcriptional factors, interferon regulatory factor-3 (IRF-3) and IRF-7, 
are activated by phosphorylation and translocated into the nucleus. IRF-3 and IRF-7 
combined with the transcriptional coactivators p300 and CREB-binding protein form a 
transcription complex which is called virus-activated factor (VAF), and this complex 
binds to the IFN-stimulated response elements (ISREs) in the promoters of particular 
cellular antiviral genes, thereby inducing their transcription. The antiviral proteins 
produced through this early IFN-independent immune response provide initial protection 
of the infected cells against viral replication. (Kim et al. 2002; Simmen et al. 2001). 
 
1.2.2 Antiviral response mediated by interferons 
Interferon (IFN) is a key component of the host defense response (reviewed in 
(Randall and Goodbourn 2008; Sadler and Williams 2008). The production and secretion 
of IFN occur in response to various external stimuli specifically including virus infection. 
IFNs bind to the receptors on cell surface and activate cellular signaling cascades which 
lead to the limitation of further spread of the disease. There are three types of interferons, 
designated as type I, II, and III, according to their amino acid sequences and the cell 
surface receptors that they bind. Type I IFNs in human contain 13 IFNα subtypes, IFNβ, 
IFNδ, IFNε, IFNκ, IFNο, and IFNτ. Type I IFN binds to the ubiquitously expressed 
heterodimeric receptor, IFNAR (IFNα receptor), which is consist of IFNAR1 and 
IFNAR2. The type II IFN only has single IFNγ gene, and is secreted by T cells and NK 
cells.  The dimer of IFNγ proteins binds to a tetramer consisting of 2 IFNGR2 (IFNγ 
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receptor 2) and 2 IFNGR1 chains. Type III IFNs have three IFNλ subtypes (IFNλ1, 
IFNλ2, IFNλ3, also referred to as IL-29, IL-28A, and IL-28B, respectively) that signal 
through IFNLR1 (IFNλ receptor 1; also known as IL-28Rα) and IL-10R2 (interleukin-10 
receptor 2; also known as IL-10R). Type III IFNs are also induced directly in response to 
viral infection and is thought to be the prototype of type I IFNs.  
IFN α and β of type I IFNs play an essential role in innate immunity. IFN α/β are 
rapidly induced in direct response to many viral infections. Cells secreting IFN-α/β have 
pattern-recognition receptors (PRRs) to detect pathogen-associated molecular patterns 
(PAMPs) such as viral dsRNA. Once activated, these PRRs induce the signaling cascades 
leading to the transcription of IFN-α/β. The simplest form for IFN-β induction requires 
IFN regulatory factor-3 (IRF-3) and nuclear factor kappa B (NF-κB). Upon stimulation, 
the cytoplasmic IRF-3 is phosphorylated, dimerized, and translocated into the nucleus. 
The inhibitor molecule, inhibitor of NF-κB (IκB) that retains NFκB in the cytoplasm, is 
also phosphorylated. The subsequent ubiquitination and degradation of IκB frees NFκB 
and results in the translocation of NFκB into the nucleus. IFN-β induction also requires 
the binding of a c-jun/ATF-2 heterodimer. The IRF-3, NFκB, and c-jun/ATF-2 
complexes assemble and form the enhanceasome on the promoter. The enhanseasome 
facilitates the recruitment of CREB-binding protein (CBP)/p300 and promotes the 
assembly of the basal transcriptional machinery and RNA polymerase II. 
IFNα/β exerts its effects through binding to the IFN-α/β receptors on neighboring 
uninfected cells as well as the initial infected cells resulting in the activation of 
JAK/STAT-dependent and STAT-independent pathways and the subsequent 
transcriptional up-regulation of several hundred IFN-stimulated genes (ISGs). Prior to 
activation, tyrosine kinase 2 (Tyk2) and the tyrosine kinase JAK1 associate with IFNAR1 
and IFNAR2, respectively. IFN binding to the receptor causes the dimerization of the 
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receptor and activates Tyk2 and JAK1 which phosphorylate STAT1 and STAT2 
subsequently. Phosphorylated STAT1 and STAT2 form a stable heterodimer and 
translocate into the nucleus where they associate with a monomer of IRF-9 to form the 
ISGF3 heterotrimer that binds to the IFN-stimulated response element (ISRE), present in 
the promoters of most IFN-responsive genes, and induces the transcription. Type III IFN 
signaling is similar to type I IFN. In type II IFN signaling, subunits of IFNγ receptor, 
IFNGR1 and IFNGR2, are associated with JAK1 and JAK2, respectively. IFNγ binding 
to the receptor activates JAK1 and JAK2 and results in the formation of STAT1-STAT1 
homodimer that translocates into the nucleus and binds to the gamma-activation sequence 
(GAS) of ISGs to stimulate the transcription (Figure 1.10).Binding of this homodimer to 
GAS does not require IRF-9. However, IFNγ can activate several ISRE-containing 
promoters, including CXCL10, by activating the formation of a heterotrimer containing 
IRF-9 and STAT1-STAT1 homodimer. 
  
Type I IFNs induced more than 300 ISGs (Der et al. 1998). The antiviral state is 
established by the combination of these ISGs which involves multiple overlapping or 
related pathways. Many of them are proteins encode pattern recognition receptors (PRRs) 
or transcription factors that form the positive feedback loop to limit the virus spread by 
detecting viral molecules and increasing the production of IFNs. Some of these ISGs 
encode proteins with the potential of direct antiviral activities through cytoskeletal 
remodeling, apoptosis induction, post-translational modification, or regulation of post-
transcriptional events. Several of these ISG proteins with potential antiviral activities 
used in my study are described in the following sections. 
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Figure 1.10 Interferons signaling through specific receptors. See text for details. 
Adapted from Sadler and Williams (2008). 
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MxA GTPases.  
The Mx proteins are members of the superfamily of dynamin-like guanosine 
triphosphatases (GTPases) and are induced exclusively by type I IFN (Haller et al. 2007). 
Mx proteins are originally identified as IFN-induced proteins with the ability to inhibit 
RNA virus replication. Mouse has evolved two distinct types of Mx GTPases to control 
viruses with different intracellular replication sites. The nuclear murine Mx1 confers 
resistance to orthomyxoviruses, including influenza A virus and Thogoto viruses, known 
to replicate in the cell nucleus. The cytoplasmic Mx2 inhibits viruses that replicate in the 
cytoplasm, such as Rhabdoviruses (vesicular stomatitis virus, VSV) and bunyaviruses (La 
Crosse virus, LACV) (Haller et al. 2007a; Haller et al. 2007b; Dreiding et al. 1985; Stertz 
et al. 2007). In human cells, the two Mx proteins, MxA and MxB, both locate in the 
cytoplasm. Human MxA acts against many viruses regardless their intracellular locations 
for replication, including members of the bunyaviruses, orthomyxoviruses, 
paramyxoviruses, rhabdoviruses, togaviruses, and picornaviruses (Kochs and Haller 
1999; Haller et al. 2007a). However, human MxB has no known antiviral activity. Mouse 
Mx1 inhibits nuclear primary transcription of the influenza virus RNA, whereas human 
MxA inhibits influenza virus replication at a later step because primary viral transcription 
is unaffected (Pavlovic et al. 1992). When artificially targeted to the nucleus, MxA, like 
Mx1, inhibits primary transcription by binding to the influenza virus polymerase PB2 and 
nucleocapsid proteins (Zurcher et al. 1992). In general, following viral infection, MxA 
binds viral nucleocapsids or other essential viral components to trap and block the 
transport or viral RNA synthesis, depending on their localizations (Kochs and Haller 
1999; Kochs et al. 2002). In addition to Mx proteins, IFNα/β also induces the expression 
of several other guanine-hydrolysing proteins that involve in host resistance to pathogens, 
including p47 guanylate-binding proteins (GBPs), the p65 GBPs, the very large inducible 
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GTPases. Only the Mx proteins have more well-characterized antiviral functions. GBP-1 
of large GTPases was shown to inhibit replication of VSV and EMCV, but the 
mechanism is unknown (Anderson et al. 1999). 
P56.  
ISG56 is one of the most highly induced ISGs in response to IFN, dsRNA, and 
many viruses (Der et al. 1998; Guo et al. 2000). The gene product, p56, is not detectable 
in untreated cells. The induction of ISG56 is transient, and the mRNA and protein turn 
over quickly (Guo et al. 2000b; Guo et al. 2000a). In humans, p56 is structurally related 
to p60, p58, and p54 proteins, all of which are induced by viral stresses and contain 
multiple tetratricopeptides (TPR) motifs which facilitate protein-protein interactions in 
huge complexes. P56 inhibits translation by interacting with the eIF3e/p48 subunit of the 
eukaryotic translation initiation factor 3 (eIF3) complex (Guo et al. 2000a) and inhibiting 
its ability to stabilize the eIF2-GTP-tRNAiMet complex (Hui et al. 2003). Therefore, p56 
has the ability to suppress translation of both virus and host proteins.  
Viperin.  
Viperin (also known as CMV-inducible gene 5, cig5) is an IFN-induced 
cytoplasmic protein involved in the antiviral response. Expression of viperin in cell-
culture systems exhibits potent antiviral activity against HCMV (Chin and Cresswell 
2001), HCV (Helbig et al. 2005), HIV (Rivieccio et al., 2006), alphaviruses (Zhang et al., 
2007), and influenza A virus (Wang et al. 2007). Viperin binds and inhibits the enzyme 
farnesyl diphosphate synthase (FPPS), which is involved in the biosynthesis of 
isoprenoid-derived lipids, and thus inhibits influenza A virus release from the plasma 
membrane by disrupting the formation of lipid rafts (which are the sites for the budding 
process of influenza viruses) on the plasma membrane (Wang et al. 2007). 
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Phospholipid scramblase 1 (PLSCR1).  
Phospholipid scramblase 1 (PLSCR1) is a calcium-binding protein which either 
inserts into the plasma membrane or binds DNA in the nucleus depending on the state of 
its palmyitoylation. It is highly induced by interferons and various growth factors (Dong 
et al. 2004). PLSCR1 suppresses viral replications of vesicular stomatitis virus (VSV) 
and encephalomyocarditis virus (EMCV) and inhibits accumulation of primary VSV 
transcripts. The antiviral effect of PLSCR1 correlated with increased expression of a 
subset of IFN-stimulated genes (ISGs), including ISG15, p54, p56, and GBPs. It is 
hypothesized that PLSCR1 is required for amplifying and enhancing the IFN response 
through increased expression of a select subset of potent antiviral genes. 
ISG15 
ISG15 is another antiviral protein that is highly induced by IFN. It is discussed in 
detail in the next section. 
1.2.3. ISG15 conjugation 
ISG15 (Interferon stimulated gene, 15kD) was originally identified as an 
interferon stimulated gene (ISG) whose expression is highly induced upon interferon 
treatment (Korant et al. 1984; Blomstrom et al. 1986; Haas et al. 1987). It is one of the 
earliest ISGs to be induced following IFN treatment or upon viral infection of human 
cells. ISG15 is also called ubiquitin cross-reactive protein (UCRP) due to its cross-
reactivity with ubiquitin antibodies (Haas et al. 1987). ISG15 is an ubiquitin (Ub)-like 
protein consisting of two ubiquitin homology domains in tandem and shows ~30% (N-
terminal domain) and ~ 36% (C-terminal domain) identical to ubiquitin. ISG15 also 
functions as a cytokine since it can be released from human lymphocytes, monocytes, and 
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epithelial cells, and induces the production of IFN-γ (Knight and Cordova 1991; D'Cunha 
et al. 1996; Recht et al. 1991). 
A major similarity between ISG15 and ubiquitin is that they both are covalently 
conjugated to targeted proteins. The first evidence for the existence of ISG15 protein 
conjugates was discovered in 1992 (Loeb and Haas 1992), and it was noted that ISG15 
conjugated proteins are non-covalently associated with the intermediate filament network 
(Loeb and Haas 1994; Narasimhan et al. 1996). The precursor of ISG15 contains 165 
amino acids and is processed to expose the C-terminal sequence LRLRGG (Potter et al. 
1999; Perry et al. 1999). After type I interferon stimulation, ISG15 becomes conjugated 
to a large numbers of cellular proteins. The C-terminal LRLRGG motif of ISG15 is 
essential to form covalent conjugates with its targets. The kinetics of the ISG15 
conjugation suggest the existence of an interferon inducible system, as free ISG15 is 
synthesized as early as two hours after IFN treatment and increases to maximal 
expression by 18 hours. In contrast, the time course of ISG15 conjugation is much 
slower, with ISG15-conjugated proteins only appearing significantly following 12-18 
hours of interferon treatment. In A549 cells, about 53% of the total ISG15 is in 
conjugated form after IFN treatment (Loeb and Haas 1992). 
ISG15 conjugation is similar to ubiquitination in that it involves an enzymatic 
cascade including E1 activating enzyme, E2 conjugating enzyme, and E3 ligase. 
However, conjugation of ISG15 to intracellular target proteins was shown to be distinct 
from that targeted by Ub (Narasimhan et al. 1996). Our laboratory identified the E1 and 
E2 enzymes in the ISG15 conjugation pathway, and showed that they are induced by 
IFN−α/β. UbE1L (E1-like ubiquitin-activating enzyme), a single-subunit enzyme 
capable of activating ISG15 but not Ub, is the E1 for ISG15 conjugation (Yuan and Krug 
2001). UbcH8 is the E2 for ISG15 conjugation (Zhao et al. 2004; Kim et al. 2004). The 
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HECT E3 ligase, Herc5 (HECT domain and RCC1-like domain containing protein 5) 
(Dastur et al. 2006; Wong et al. 2006; Takeuchi et al. 2006) has been shown to be the 
major E3 for ISG15 conjugation. Like Ub, ISG15 is removed from conjugated proteins 
by a specific protease, USP18 (Malakhov et al. 2002). All enzymes identified in ISG15 
conjugation pathway so far are induced by type I IFNs. UbcH8 was also reported to be a 
ubiquitin-conjugating enzyme, but it is clear now that UbE1L selectively binds to UbcH8 
(Durfee et al. 2008) and favors ISG15 conjugation. In addition to the major enzymes 
described above, UbcH6 (Takeuchi et al. 2005) and EFP (estrogen-responsive finger 
protein; also called TRIM25) (Zou and Zhang 2006) are also identified as E2 and E3 for 
ISG15 conjugation, respectively. (Figure 1.11) 
The biological functions of protein ISG15 conjugation in cells remain to be 
elucidated. At least 158 ISG15 conjugation targets in human cells have been identified so 
far (Zhao et al. 2005; Giannakopoulos et al. 2005). The identity of these ISG15 target 
proteins provides opportunities to study the function of ISG15 conjugation. Most target 
proteins are constitutively expressed and function through diverse cellular pathways, such 
as RNA splicing, stress response, chromatin remodeling, transcription, and translation. 
Twelve of the ISG15 target proteins are IFN α/β induced proteins. Nine of these 
IFN−α/β induced proteins can be characterized as antiviral proteins: PKR, MxA, GBP-1, 
HuP56, HuP54, HuP60, HuP58, RIG-I, and STAT1 (Zhao et al. 2005). One possibility is 
that ISG15 modification of these IFN−α/β induced antiviral proteins increase their 
stability and/or activity. ISG15 might also change the activities of its target proteins, 
perhaps by altering their localization or association with other proteins. 
Modification by ISG15 does not appear to target proteins for proteasomal 
degradation. One function of ISG15 might be to stabilize proteins that would otherwise 
be targeted for Ub-mediated degradation. ISG15 has been reported to prevent virus- 
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Figure 1.11 Schematic diagram of ISG15 conjugation pathway. See text for details. 
Adapted from Sadler and Williams (2008). 
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mediated degradation of IFN-regulatory factor 3 (IRF-3) and increase the induction of 
IFN-β expression (Lu et al. 2006).  
ISG15 and/or its conjugation are proposed to have a role in the innate immune 
response to viral or bacterial infection. Although ISG15 knockout (ISG15-/-) mice show 
neither defect in the antiviral response against vesicular stomatitis virus (VSV) and 
Lymphocytic Choriomeningitis virus (LCMV) nor enhanced STAT1 signaling (Osiak et 
al. 2005), these mice have increased susceptibility to influenza A and B viruses, Sindbis 
virus, Herpes simplex virus 1 (HSV-1) and murine γ –herpesvirus. Increased lethality and 
virus replication in multiple organs during virus infection in ISG15-/- mice provided 
strong evidence that ISG15 and/or its conjugation have antiviral function (Lenschow et 
al. 2005; Lenschow et al. 2007). One hypothesis is that ISG15 functions by antagonizing 
ubiquitin’s activity by competing for ubiquitin conjugation sites on specific host or viral 
proteins. This is supported by recent studies that overexpression of ISG15 suppresses the 
ubiquitination of viral proteins that is required for efficient virus release, via inhibiting 
ubiquitination of HIV proteins Gag and Tsg101 (Okumura et al. 2006) or inhibiting the 
Nedd4 Ub E3 activities in Ebola virus infected cells (Malakhova and Zhang 2008). In the 
case of HIV-1 and Ebola virus, the antiviral function is most likely mediated by free 
ISG15 alone (Malakhova and Zhang 2008; Okumura et al. 2006). In contrast, a study of 
the effect of ISG15 on Sindbis virus replication provided initial evidence that ISG15 
conjugation may be responsible for the antiviral activity (Lenschow et al. 2005). 
Specifically, the C-terminal LRLRGG motif of ISG15, which is required for conjugation, 
is also required for antiviral activity against Sindbis virus. In addition, infection of 
influenza B virus strongly induces the expression of free ISG15 protein, but NS1B 
protein blocks protein ISG15 conjugation through direct interaction with ISG15 at its N-
terminus (Yuan et al. 2002; Chang et al. 2008). This finding indicates that ISG15 
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conjugation is likely to be an important part of the IFN α/β-induced antiviral response. 
The ISG15 conjugation targets involved in the antiviral activities could be host proteins 
that either directly affect viral replication or in some way modulate the innate immune 
response. Alternatively, ISG15 could conjugate to viral proteins and inhibit their 
functions. Modification of viral proteins by either ubiquitin or UBLs, such as SUMO, has 
been seen with both RNA and DNA viruses. However, although a large number of 
cellular proteins are ISG15 conjugated, ISG15 conjugation of a virus-encoded protein has 
not yet been reported. 
Instead, ISG15 antiviral activity may be completely independent of its ability to 
modify target proteins. Human ISG15 has been reported to be a cytokine. Therefore, in 
addition to its ability to conjugate to intracellular proteins, ISG15 may also function as a 
cytokine whose activity could impact upon either the innate or adaptive immune 
response. But the conjugation and cytokine activity of ISG15 might still be linked, since 
it has been reported that the cytokine activity of ISG15 requires the terminal diglycine 
(D'Cunha et al. 1996), and a high molecular mass form of ISG15 is present in the serum 
of infected mice (Lenschow et al. 2007).  
The increased susceptibility to influenza A virus infection of ISG15-/- mice was 
not observed when mouse embryo fibroblasts derived from these mice were used in tissue 
culture experiments (Lenschow et al. 2007). These investigators postulated that the 
analysis of the effects of ISG15 and/or its conjugation on influenza A virus replication 
had to be carried out in vivo in mice. In this thesis, we focus on human tissue culture 
cells, and demonstrate that IFN-induced ISG15 conjugation inhibits influenza A virus 
replication in these cells. Consequently, human tissue culture cells provide a tractable 
system to delineate how ISG15 conjugation inhibits influenza A virus replication.  
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Chapter 2 : ISG15 conjugation has anti-influenza effect and can be 
examined in human tissue culture models  
 
2.1 INTRODUCTION 
Virus infection activates the synthesis of type I interferons (IFN-α and IFN-β), 
which induce hundreds of IFN-stimulated genes (ISG), many of which play crucial roles 
in the antiviral response (Biron and Sen 2001; Randall and Goodbourn 2008; Sadler and 
Williams 2008). One of the earliest and most strongly induced proteins is ISG15, a 15-
kDa ubiquitin-like protein that becomes conjugated to many cellular proteins through its 
C-terminal LRLRGG motif (Korant et al. 1984; Blomstrom et al. 1986; Haas et al. 1987; 
Loeb and Haas 1992; Loeb and Haas 1994; Narasimhan et al. 1996; Malakhov et al. 
2003; Zhao et al. 2005; Giannakopoulos et al. 2005; Wong et al. 2006; Pattyn et al. 
2008). The three enzymes in human cells that catalyze this conjugation, the UbE1L E1 
enzyme, the UbcH8 E2 enzyme and the Herc5 E3 ligase, as well as the deconjugating 
enzyme, UBP43, are also induced by IFN-α/β . (Yuan and Krug 2001; Zhao et al. 2005; 
Dastur et al. 2006; Wong et al. 2006; Malakhov et al. 2002) Although it had been 
reported that UbcH8 functions in both ISG15 and ubiquitin conjugation (Kumar et al. 
1997; Zhang et al. 2000; Chin et al. 2002; Dastur et al. 2006; Wong et al. 2006), a recent 
study demonstrated that UbcH8 is unlikely to function in ubiquitin conjugation in vivo, 
based on the high Km of the E1 ubiquitin-activating enzyme for UbcH8 and on the low 
level of UbcH8 expression in the absence of IFN treatment (Durfee et al. 2008). A large 
number of human proteins that are targets for ISG15 conjugation have been identified 
(Zhao et al. 2005; Giannakopoulos et al. 2005; Wong et al. 2006; Pattyn et al. 2008). 
Most of these targets are constitutively expressed proteins that function in diverse cellular 
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pathways, but several of the targets are IFN-α/β induced antiviral proteins, including 
MxA, GBP-1, HuP56 (p56), RIG-I,  PKR, HuP54, HuP60, HuP58, and STAT1. The 
exact function of ISG15 conjugation is still not clear, but ISG15 modification of these 
IFN−α/β induced antiviral proteins may increase their stability, activity, and/or 
interaction with other proteins 
The rapid induction of ISG15 after viral infection and the existence of ISG15-
conjugated antiviral proteins has raised the speculation of ISG15 being an antiviral 
molecule. Because the NS1 protein of influenza B virus (NS1B) was shown to bind 
ISG15 and inhibit its conjugation to target proteins, it was proposed that ISG15 and/or its 
conjugation are inhibitory to the replication of influenza B virus (Yuan and Krug 2001). 
In addition, ISG15 overexpression was shown to inhibit the release of HIV-1 virions in 
vitro (Okumura et al. 2006). Subsequently, experiments using ISG15-knockout (ISG15-/-
) mice established that ISG15 and/or its conjugation inhibits the replication of not only 
influenza B virus but also influenza A virus (Lenschow et al. 2007). For example, at one 
of the inoculum levels employed for influenza A virus, 52% of the ISG15-/- mice died, 
whereas significantly less, 23%, of the ISG15+/+ mice died. However, the effect of 
ISG15 and/or its conjugation on virus replication was not detected in mouse embryo 
fibroblasts (MEFs) in tissue culture. MEFs only supported very limited replication of 
influenza A virus, and there was no significant difference in virus replication between 
ISG15+/+ and ISG15-/- MEFs (Lenschow et al. 2007). These investigators postulated 
that influenza A virus replication was probably selectively spared in other, not yet 
identified cell types of the ISG15-/- mouse and that analysis of the effects of ISG15 
and/or its conjugation on influenza A virus replication had to be carried out in vivo in 
mice. 
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In the present study we focus on human tissue culture cells and on the effect of 
ISG15 and/or its conjugation on the replication of influenza A virus in such cells. We 
show that IFN-induced antiviral activity against influenza A virus is significantly 
alleviated by blocking ISG15 conjugation using small interfering RNAs (siRNAs) against 
ISG15 conjugating enzymes, thereby demonstrating that IFN-induced ISG15 conjugation 
inhibits influenza A virus replication in human tissue culture cells. Unconjugated ISG15 
does not contribute to this antiviral activity because the siRNA knockdowns had 
essentially no effect on the level of free ISG15. Finally, we used siRNA knockdowns in 
human cells to demonstrate that other IFN-induced proteins, specifically p56, MxA and 
phospholipid scramblase 1, also inhibit influenza A virus gene expression. 
 
  
2.2 MATERIALS AND METHODS 
2.2.1 Cell lines 
A549 human lung carcinoma cells (ATCC CCL-185), Vero African green 
monkey kidney cells (ATCC CCL-81), Madin–Darby canine kidney (MDCK) (ATCC 
CCL-34), and Calu3 (ATCC HTB-55) were purchased from ATCC. ISG15 wt (ISG15 
+/+) and ISG15 knockout (ISG15 -/-) mouse embryo fibroblasts were kindly provided by 
Dr. Klaus-Peter Knobeloch and Dr. Ivan Horak (Osiak et al. 2005). MEFs, A549, Vero, 
and MDCK cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
(GIBCO®) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(GIBCO®), 2 mM l-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin 
(GIBCO®) at 37°C under a 5% CO2/95% air atmosphere. Calu3 cells were grown in 
Advanced MEM (GIBCO®) supplemented with 10% heat-inactivated fetal bovine serum 
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(FBS), 2 mM l-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin at 37°C 
under a 5% CO2/95% air atmosphere. 
 
2.2.2 RNA interference.  
All siRNA duplexes were synthesized by Invitrogen and resuspended in DEPC-
treated water to a final storage concentration of 20µM. siRNA sequences used in the 
experiment are listed in table 1.1 (only one strand of each siRNA duplex is shown). For 
ISG15, UbE1L, and UbcH8 RNAi, ISG15 conjugation knockout efficiency of each 
siRNA duplex was examined by transfecting siRNA into A549 cells followed by 24-hour 
human IFN-β treatment. Both UbcH8 siRNA duplexes showed the same high efficiency 
for ISG15 conjugation knockout (more than 90% reduction of UbcH8 protein expression 
and ISG15 conjugation in western blot analysis). Each of the three ISG15 siRNA 
duplexes showed similar 50-60% reduction of ISG15 conjugation and relatively low, if 
not none, reduction of free ISG15 protein level. Each of the three UbE1L siRNA 
duplexes also showed 50-60% reduction of ISG15 conjugation. However, when applying 
ISG15 and UbE1L RNAi together, ISG15 conjugation were efficiently reduced to the 
level comparable to that of UbcH8 knockout experiments, i.e., more than 85-90% 
reduction in ISG15 conjugation. All nine combinations of ISG15- and UbE1L- siRNA 
duplexes used in these double knockout experiments had the same extent of effects in 
reducing ISG15 conjugation. For MxA RNAi, both siRNA duplexes were effective and 
knocked down about 80% of the IFN-induced MxA protein expression. A pool of all 
three siRNAs was used to knockout p56, p54, phospholid scramblase 1 (PLSCR1), GBP-
1, or viperin. 
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Table 2.1 Sequences of siRNA used in present study.  
siRNA Sequence (sequence of complimentary strand not shown) 
UbcH8 (a) 5’-CCUACCACCUGAAAGCCUUdTdT 
UbcH8 (b) 5’-GACGAGAACGGACAGAUUUdTdT 
ISG15 (a) 5’-AAUCUUCUGGGUGAUCUGCGCCUUC 
ISG15 (b) 5’-AGAGGUUCGUCGCAUUUGUCCACCA 
ISG15 (c) 5’-CCCUUGUUAUUCCU-CACCAGGAUGC 
UbE1L (a) 5’-UAGUGCUGGCGUCUCAGUUUCUCCU 
UbE1L (b) 5’-UAAGGUGAGUGUCUGUGGCUCAUCC 
UbE1L (c) 5’-UUCCCGAGAAAGUCACCAAGUCUCC 
MxA (a) 5’-GGAAGCUGUGAGAGCAGUUUGGUUU 
MxA (b) 5’-GCUUGCUUUCACAGAUGUUUCGAUA 
p56 (a) 5’-ACAGAGUCUUGGAUCAGAUUGAAUU 
p56 (b) 5’-ACUUAAUGCAGGAAGAACAUGACAA 
p56 (c) 5’-GCAACUUUGCCUGGAUGUAUUACCA 
Phospholipid scamblase 1 (a) 5’-GGAAACAAACUUGCCAGUUGGGUAU 
Phospholipid scamblase 1 (b) 5’-ACUGUCCACCUGGAUUAGAAUAUUU 
Phospholipid scamblase 1 (c) 5’-GCAGCGGAAGAUACUGAUUGCUGUA 
GBP-1 (a) 5’-UCCUUUCUGCCAUUACACAGCCUAU 
GBP-1 (b) 5’-ACGGUGCAGUCUCACACUAAAGGAA 
GBP-1 (c) 5’-GAAGCUUGCCCAGCUCGAGAAACUA 
Viperin (a) 5’-ACAUAUGGAGU-AAGGCUGAUCUGAA 
Viperin (b) 5’-GGUUCCAGAAUUAUGGUGAGUAUUU 
Viperin (c) 5’-GGAAGCUCUU-GAGUGUGUUCAGGCA 
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For obtaining the maximal RNAi effect, confluent A549 cells were trypsinized, 
washed, and resuspended in serum- and antibiotics-free Opti-MEM at 3×105 cells per ml. 
For Calu3 cells, the cells were resuspended at 6×105 cells per ml. 2.5ml cell suspension 
was seeded into one well of a 6-well tissue culture plate immediately before siRNA 
transfection. For each siRNA transfection, Xtreme® siRNA transfection reagent (Roche) 
was diluted with Opti-MEM I (Invitrogen) and incubated at room temperature for 5 
minutes. SiRNA was mixed with Opti-MEM I and added to the diluted transfection 
reagent in a ratio of 2.5µl reagent/20nM siRNA(final concentration after added to cells), 
and the mixture was incubated at room temperature for additional 25 minutes. The 
transfection complex was then added to A549 cells. The plate was gently rocked to mix 
the cells and transfection complex. Final concentration of siRNA in each well was 20nM, 
except for ISG15 and UbE1L double knockdown, where 40nM of UbE1L and 60nM of 
ISG15 siRNAs were used. SiRNA-transfected cells were incubated in serum- and 
antibiotics-free Opti-MEM I (Invitrogen) for 12-24 hours at 37°C. The culture medium 
was replaced with DMEM supplemented with 10% heat-inactivated FBS, 2mM L-
glutamine, 100 units/ml penicillin, and 100µg/ml streptomycin for A549 cells, or 
Advanced MEM with 10%FBS and penicillin-streptomycin-glutamine for Calu3 cells.  
Where indicated, human interferon β (100-1000u/ml) (Betatheron®, Berlix Co.) was 
added. Cells were mock- or IFN-β- treated for 24 hours prior to influenza A virus 
infection. 
 
2.2.3 Virus infection 
Recombinant influenza A/Udorn/72 (Ud) virus stocks were amplified in 10-day 
fertilized eggs, and the virus titers were determined by plaque assays in Madin-Darby 
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canine kidney (MDCK) cells (described in details in “Methods and Materials” of chapter 
3). For single-cycle virus infections, cells (A549, Calu3, or MEFs) were infected with the 
Ud virus at a high multiplicity of infection (moi) of 5 plaque-forming units (pfu)/cell. In 
brief, cells were washed twice with PBS to remove remnant serum in the culture medium 
before infection. Influenza virus was diluted in serum-free DMEM and added to the 
washed cells at multiplicity of infection (MOI) of 5 pfu/cell. After 1h adsorption at 37°C, 
cells were washed once with PBS, replenished with infection media, and the cells were 
incubated at 37°C under 5% CO2 for indicated time. For protein analysis, the infection 
medium is composed of DMEM with 2% heat-inactivated FBS and penicillin-
streptomycin (A549, Vero, and MEFs) or Opti-MEM I containing 2% FBS and 
antibiotics (Calu3 cells). For virus analysis in Calu3 cells, infection medium was 
composed of Opti-MEM I, 2.5µg/ml N-acetylated trypsin, and penicillin-streptomycin. 
At time-point indicated, supernatants were collected from the culture media of infected 
cell, and virus titers were determined by plaque assay in MDCK cells.  
ISG15+/+ and ISG15-/- MEFs were split into 6-well tissue culture plates. When 
cells reach 90% confluency, culture media were changed with or without 1000u/ml 
recombinant mouse interferon beta (Sigma-aldrich, I9032). After 24h interferon 
treatment, MEFs were infected by influenza A/WSN/33, A/PR8, or A/Udorn/72 virus at a 
high multiplicity of 5 pfu/cell for 6 hours. 
Wild-type vesicular stomatitis virus (VSV) was kindly provided by Dr. Robert H. 
Silverman (Cleveland Clinic). VSV was propagated, and the titer of the virus stock was 
measured by plaque assays in Vero cells. In short, viral infections were performed in 
serum-free DMEM for one hour. After the incubation, infection medium was replaced 
with DMEM containing 2% FBS and antibiotics for virus propagation, or fully 
supplemented growth medium for protein analysis. The plaque assay in Vero cells is 
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modified from plaque assays in MDCK cells. One hour post-infection, virus inoculum 
was removed and replaced with 1% agarose resuspended in DMEM containing 2%FBS 
and penicillin-streptomycin. Three days post-infection, agarose was removed and the 
cells were fixed with 4% formaldehyde in PBS for 30 minutes at room temperature. Cells 
were then stained with 0.2% crystal violet resuspended in 20% ethyl alcohol, and washed 
with water. Virus plaques were counted to determine the virus production.  
  
2.2.4 RNA Extraction, Reverse Transcription (RT), Semi-quantitative RT-PCR, and 
Northern analysis 
A549 cells were transfected with either control or ISGylation pathway-specific 
siRNAs, IFN-treated, and infected with influenza A/Udorn/72 virus for 8 hours. After 8 
hours of infection, culture medium was removed, and cells were washed once with PBS. 
Cells were then lysed, and total RNA was harvested by using Trizol reagent (Invitrogen) 
according to manufacturer’s instructions. cDNAs of vRNA, cRNA, or mRNA of NS gene 
were produced by employing 1µg of total RNA and 10pmol specific primers for reverse 
transcription using Transcriptor First Strand cDNA Synthesis Kit (Roche) in a 20µl 
reaction mixture. 5µl mixture of RT reaction was then mixed with NS gene specific 
primers and platinum PCR supermix (Invitrogen) for semi-quantitative PCR analysis. 
PCR were terminated at 20, 25, and 30 cycles. Amplified PCR products were visualized 
by 1% agarose electrophoresis. For Northern blot analysis, 10µg total RNA/sample was 
separated on 1.2% agarose gel. RNA was then transferred and UV-crosslinked onto nylon 
membrane (Nytran®, Whatman Schleicher & Schuell). To prepare the 32P-labeled probes 
for NS1, the PCR product of full-length NS gene was used as template for the random 
priming reaction. Random primers were produced by Klenow fragment in the presence of 
α-32P -dCTP using RadPrime® DNA labeling system (Invitrogen). Unincorporated 
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nucleotides were removed by using ProbeQuant 50 (GE Healthcare). After hybridization, 
signal strength was determined by scanning the activated phosphor imaging screen (Bio-
Rad) with Typhoon Trio (GE Healthcare) and analyzed by ImageQuant software. 
2.2.5 Antibodies and Immunoblotting 
Antibodies against the following proteins were used to probe immunoblots: 
human ISG15; influenza A virus NS1A protein; UbcH8 (Abgent); mouse ISG15 (Osiak 
et al. 2005); the major structural proteins of influenza A/Udorn/72 virus, which detects 
the HA, NP and M1 (matrix) proteins, provided by Dr. Robert A. Lamb (Northwestern 
University); p56, provided by Dr. Ganes Sen (Cleveland Clinic); VSV N protein, 
provided by Dr. Robert H. Silverman (Cleveland Clinic); MxA, provided by Dr. Otto 
Haller (Universitätsklinikum Freiburg); and viperin, provided by Dr. Peter Cresswell 
(Yale University). 
Cells collected at the indicated time were extracted in RIPA buffer (50mM Tris-
Cl, pH 7.5, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) 
supplemented with Complete® protease inhibitor (Roche). Proteins (30µg/sample) were 
separated on 12% polyacrylamide-sodium dodecyl sulfate gels (SDS-PAGE) and 
transferred onto nitrocellulose membrane (Bio-Rad) by semi-dry transfer method at 
0.8mA/cm2. Blots were blocked in TBS containing 0.2% Tween (TBST) and 5% non-fat 
dried milk at room temperature for 1 h and then incubated with primary antibodies in the 
same blocking buffer at room temperature for 1 h or at 4°C overnight. The blots were 
washed three times with TBST. Secondary antibodies, rabbit anti-mouse IgG-HRP (Santa 
Cruz), donkey anti-rabbit IgG-HRP (GE Amersham), or donkey anti-goat IgG-HRP 
(Santa Cruz) were diluted (1:10000) in blocking buffer. Membranes were incubated in 
these diluted secondary antibodies for an hour at room temperature and washed four 
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times with TBST. Proteins were detected with enhanced chemiluminescence (ECL) 
western blotting substrate (Pierce) and exposed to CL-Xposure film (Pierce). 
2.3 Results 
2.3.1 SiRNA knockdown of ISG15 conjugation alleviates the IFN-induced inhibition 
of influenza A virus gene expression 
The basic experimental design is diagrammed on the top of Figure 2.1. Human 
A549 cells were treated with a high level of IFN-β (1000 units/ml) for 24 hours to 
achieve sufficient ISG15 conjugation. As a control, a different set of cells was not treated 
with IFN. Twenty-four hours prior to IFN treatment, the cells were transfected with 
siRNA(s) directed against the enzyme(s) in the ISG15 conjugation pathway to selectively 
suppress IFN-induced ISG15 conjugation. As a control, another set of cells was treated 
with scrambled control siRNA. After the successive siRNA and IFN treatments, the cells 
were infected with influenza A/Udorn/72 (Ud) virus at a high multiplicity of infection 
(moi) 5 pfu/cell for 8 hours, and the synthesis of viral proteins and RNAs was measured 
by immunoblots (WB) and northern blots (NB) as described below. 
We first targeted UbE1L, the E1 enzyme in ISG15 conjugation (Yuan and Robert 
M. Krug 2001). However, siRNA knockdown of UbE1L in A549 cells alone did not 
achieve efficient inhibition of ISG15 conjugation, and it was necessary to add a siRNA 
directed against ISG15 itself. As analyzed by an immunoblot, the combination of these 
two siRNAs effectively eliminated IFN-induced ISG15 conjugation (Figure 2.1 (A), 
compare lanes 3 and 4). In contrast, only a minimal reduction in free ISG15 occurred. 
Consequently, it was not clear why it was necessary to add the siRNA directed against 
ISG15 to achieve efficient inhibition of ISG15 conjugation. Other experiments in which 
we used siRNAs against only ISG15 also failed to effectively reduce the amount of IFN- 
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Figure 2.1 Knocking down ISG15 conjugation by RNAi alleviates the inhibition on 
viral gene expression induced by IFN-β. A549 cells treated with siRNAs 
and IFN-β, as shown in the schematic diagram of experimental design, were 
infected by influenza A/Udorn/72 viruses at m.o.i. of 5 pfu/cell for 8 hours. 
(A) Western blot analysis showed that ISG15 conjugation induced by IFN 
was knocked down by combined treatment of ISG15 and UbE1L siRNAs. 
Influenza viral protein expression (NS1) was partially rescued in these 
knocked down cells. (B) Northern blot analysis and (C) semi-quantitative 
RT-PCR analysis indicated that increased viral RNA synthesis were also 
presented in these ISGylation-knocked down cells. 
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induced ISG15 (data not shown). By knocking down ISG15 conjugation with the UbE1L 
and ISG15 siRNAs, the synthesis of the viral NS1A protein was partially rescued (Figure 
2.1(A)). The amount of the NS1A protein in the cells transfected with these two siRNAs 
(lane 4) was approximately 10-fold higher than in the cells transfected with the control 
siRNA (lane 3). The amount of the restored NS1A protein was approximately 15% of the 
amount produced in infected cells not treated with IFN (compare lane 4 to lanes 1 and 2). 
A similar restoration of the synthesis of NS1A RNA was observed in the cells treated 
with the two specific siRNAs, as assayed by Northern blot analysis (Fig. 2.1 (B)). Semi-
quantitative RT-PCR analysis confirmed the northern blot result and further revealed that 
it was a combined effect of increases in all 3 RNA species, cDNA, vRNA, and mRNA 
(Fig. 2.1(C)). Consequently, we concluded that ISG15 conjugation inhibits the synthesis 
of both the NS1A protein and its viral RNAs.  
To verify that ISG15 conjugation rather than free ISG15 mediated this inhibition 
of NS1A protein synthesis, we used an siRNA that targeted UbcH8 (Figure 2.2) (Zhao et 
al. 2004; Dastur et al. 2006; Wong et al. 2006; Durfee et al. 2008). The UbcH8 siRNAs 
effectively inhibited ISG15 conjugation, whereas no effect on the accumulation of free 
ISG15 was detected (Figures 2.2(A)). The effect of the UbcH8 siRNA on NS1A protein 
synthesis was similar to that obtained in the experiment using the UbE1L plus ISG15 
siRNAs (Figures 2.2(B)): (i) the amount of the NS1A protein in the cells transfected with 
the UbcH8 siRNA (lane 4) was 10-20-fold higher than in the cells transfected with the 
control siRNA (lane 3); and (ii) the amount of rescued NS1A protein level was 15-20% 
of that in cells not treated with IFN (compare lane 4 to lanes 1 and 2). These results 
verify that ISG15 conjugation rather than free ISG15 inhibits the synthesis of the 
influenza A virus NS1A protein in human cells. 
 51
 
 
 
 
Figure 2.2 Eliminating ISGylation by knocking down UbcH8 also relieves the 
inhibition of IFN-β on influenza viral protein expression.  (A) ISG15 
conjugation in A549 cells induced by IFN-β treatment was knocked out by 
UbcH8 siRNA treatment. (B) UbcH8 siRNA and IFN-β treated A549 cells 
were infected by influenza A/Udorn/72 viruses. Inhibition on viral protein 
expression by IFN treatment was partially relieved in these cells. 
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To determine whether ISG15 conjugation similarly inhibits the synthesis of other 
influenza A virus proteins, we measured the production of the major viral structural 
proteins using an antibody raised against Ud virions (Figure 2.3). Knocking down ISG15 
conjugation with the siRNAs directed against UbE1L and ISG15 rescued the synthesis of 
not only the NS1A protein but also the HA, NP and M1 structural proteins. Similar to the 
situation with the NS1A protein, the amount of these three structural proteins in cells 
transfected with the UbE1L and ISG15 siRNAs (lane 4) was approximately 20-fold 
higher than in the cells transfected with the control siRNA (lane 3); and the rescued HA, 
NP and M1 protein levels were 15-20% of the levels in cells not treated with IFN 
(compare lane 4 to lanes 1 and 2). Consequently, ISG15 conjugation inhibited the 
synthesis of most, if not all influenza A virus-encoded proteins. 
In the study of characterizing the ISG15 antiviral activity in ISG15-/- mice, these 
mice are more susceptible to infection of influenza, sindbis, and herpex simplex virus 
type I, but no defects were found in their responses to vesicular stomatitis virus (VSV) or 
lymphocytic choriomeningitis virus (LCMV). We decided to examine if ISG15 
conjugation had antiviral effect against VSV infection in human tissue culture cells as 
seen with influenza virus infection. ISG15 conjugation in A549 cells were knocked down 
by RNAi as previously described. The cells were then IFN-treated for 24 hours prior to 
VSV infection at a high multiplicity of 5 pfu/cell. VSV N protein expression was heavily 
inhibited in IFN-treated cells (Figure 2.4. Compare lanes 6 and 8 to lanes 1 and 2). But, 
unlike influenza A virus infection, no significant increase of the protein expression of 
VSV N protein was found in cells where ISG15 conjugation is knocked down by UbcH8 
RNAi (Figure 2.4. Compare lanes 6 and 8). This result was consistent with the findings 
that ISG15 -/- mice was resistant to VSV infection.  
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Figure 2.3 Eliminating ISGylation in IFN-β treated cells rescues the protein 
expression of most viral proteins of influenza A virus. ISG15 conjugation 
in A549 cells induced by IFN-β treatment was knocked out by ISG15 plus 
UbE1L siRNAs. Viral protein expressions were analyzed by western blot 
using specific antibodies.  
 54
 
 
Figure 2.4 Knocking down ISG15 conjugation in IFN-β treated A549 cells does not 
relieve the inhibition on VSV viral protein expression.  A549 cells were 
siRNA and IFN-β treated as indicated in the schematic diagram. Cells were 
then infected by VSV at MOI of 5 pfu/cell for 8 hours. Viral protein 
expression was examined by western blot analysis using antibody against 
the N protein of VSV. 
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2.3.2 The inhibition of influenza A virus gene expression by ISG15 conjugation in 
human cells is sufficient to result in inhibition of virus replication 
To determine whether ISG15 conjugation inhibits the replication of influenza A 
virus in human cells, we used Calu3 cells which afford high replication rates of influenza 
A virus (Zeng et al. 2007). We measured the production of progeny virus in IFN-treated 
Calu3 cells that had been transfected either with the control siRNA or with both the 
UbE1L and ISG15 siRNAs (Figure 2.5). Transfection of Calu3 cells with the control 
siRNA in the absence of IFN treatment induced some ISG15 conjugation (Figure 2.5 A, 
lane 1), thereby presumably potentiating subsequent IFN-induced ISG15 conjugation 
(lane 3). Nonetheless, the UbE1L and ISG15 siRNAs inhibited ISG15 conjugation in 
Calu3 cells approximately 90% (lane 4), and the amount of the NS1A protein synthesized 
in cells transfected by these two siRNAs was 10-15-fold higher than in cells transfected 
with the control siRNA (compare lanes 3 and 4). The effect on virus replication was 
similar: the rate of virus replication during the first 4 hours of infection in cells 
transfected with these two siRNAs was approximately 10-20 fold greater than in cells 
transfected with the control siRNA (Figure 2.5B). We conclude that ISG15 conjugation 
in human cells inhibits influenza A virus replication. 
2.3.3 The anti-influenza activities of ISG15 conjugation in mouse and human cells 
are different.  
ISG15-/- mice had higher susceptibility to influenza A viruse infection than wild-
type mice, and the virus titer was also higher in the lungs of these infected ISG15-/- mice. 
However, the differences of virus production were not detected when ISG15 +/+ and 
ISG15 -/- MEFs were used; viral growth of influenza A virus was limited in both MEFs 
(Lenschow et al. 2007). We examined the influenza A virus gene expression in these 
MEFs in a setting similar to that used in the siRNA experiment. 
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Figure 2.5 The inhibition of influenza A virus gene expression by ISG15 
conjugation in human cells is sufficient to result in inhibition of virus 
replication. ISG15 conjugation induced by IFN-β treatment in Calu3 cells 
were knocked down by RNAi as described previously. Cells were 
subsequently infected by influenza A/Udorn/72 virus for 8 hours. 
Supernatants from infected cells were collected every two hours post-
infection for plaque assay analysis. (A) Cell lysates were harvested 8 hours 
after infection for western blot analysis (B) Virus production from each time 
point was measured by plaque assays in MDCK cells. 
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 ISG15+/+ and ISG15-/- MEFs were treated with or without mouse IFN-β for 24 hours, 
and infected with A/WSN/33, A/PR8, or A/Udorn/72 influenza viruses at high 
multiplicity for 6 hours. ISG15 conjugation was greatly induced in ISG15+/+ MEFs, but 
was not seen in ISG15-/- MEFs. Notably, in ISG15+/+ MEFs without interferon 
treatment, mild level of ISG15 conjugation was detected. Influenza NS1A protein was 
expressed at high level in non-IFN treated MEFs; the mild ISGylation detected in 
ISG15+/+ MEFs did not affect the protein synthesis. In IFN-treated MEFs, the NS1A 
protein expression was heavily inhibited, and there was no significant difference of the 
NS1A protein expression between ISG15 +/+ and ISG15 -/- MEFs (Figure 2.6). This 
result is consistent with the previous findings that viral replication was not increased in 
infected ISG15 +/+ or ISG15 -/- MEFs. However, in our study, we have shown that in 
human tissue culture cells, ISG15 conjugation knockdown is correlated with increased 
influenza viral protein expression and virus production. These findings indicate that the 
MEFs are not the suitable mouse cell lines to study the function of ISG15 conjugation, or, 
the anti-influenza activity in mouse and human might function through different 
mechanisms. The latter hypothesis is more preferable as research in our lab indicates that 
NS1 protein of influenza B virus specifically binds to human ISG15, but not to mouse 
ISG15 (data not shown), suggesting a specific role of ISG15 conjugation in antiviral 
activity in human cells. Unlike ubiquitin, which is highly conserved (>95%) among 
different species, human and mouse ISG15 proteins only has 66.7% homology (NCBI 
HomoloGene).  
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Figure 2.6 Influenza viral protein expression was not rescued in IFN-β treated 
ISG-/- MEFs. ISG15+/+ and ISG15 -/- MEFs were either mock-treated or 
IFN-treated for 24 hours. Cells were then infected with either A/WSN/33 or 
A/Udorn/72 viruses. Protein expression of NS1A and ISG15 conjugation 
were detected by western blot analysis. 
 
 59
2.3.4 SiRNA knockdown of several other IFN-induced proteins alleviates the IFN-
induced inhibition of influenza A virus gene expression in human cells 
Our observation that siRNA knockdown of IFN-induced ISG15 conjugation only 
partially relieves the antiviral effect of IFN treatment on influenza A virus gene 
expression and replication in human cells indicates that, as to be expected, other IFN-
induced proteins also contribute to the IFN-induced inhibition of influenza A virus 
replication. To identify at least some of these antiviral proteins, we transfected siRNAs 
directed against each of several IFN-induced proteins with known or suspected antiviral 
activities against other viruses (Figure 2.7). We used the same basic experimental design 
as employed for the siRNA knockdowns of IFN-induced ISG15 conjugation. SiRNAs 
against p56, MxA and phospholipid scramblase 1 (PLSCR1) rescued the synthesis of the 
viral NS1A protein to essentially the same extent as the siRNA knockdown of ISG15 
conjugation, demonstrating that these three IFN-induced proteins inhibit influenza A 
virus gene expression. In contrast, rescue was not detected using the siRNA directed 
against GBP-1, but since we did not have antibody against the GBP-1 protein, we could 
not determine whether GBP-1 expression was efficiently reduced by the siRNA. The 
siRNA against viperin, which efficiently reduced the amount of this protein, caused at 
most a marginal rescue of the synthesis of the NS1A protein; consistent with the evidence 
that viperin predominantly inhibits release of the virus from the plasma membrane, a step 
that occurs after most viral protein synthesis (Wang et al. 2007). The minimal effect 
caused by viperin siRNA serves as an additional negative control for these siRNA 
knockdown experiments, verifying that the rescue of influenza A virus gene expression 
caused by siRNAs directed against other IFN-induced proteins demonstrates that such 
IFN-induced proteins contribute to the IFN-induced antiviral activity against influenza A 
virus. 
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Figure 2.7 HuP56, MxA and phospholipid scramblase 1 RNAi also rescued 
influenza viral protein expression inhibited by IFN-β treatment. A549 
cells were transfected with different antiviral siRNAs and treated with IFN-
β for 24 hours. Cells were subsequently infected with influenza A/Udorn/72 
viruses. Viral protein expression (NS1) was examined to reveal the rescue 
effects of knocking down these antiviral proteins. (A) Effect of p56 
knockdown was compared to that of the ISGylation knockdown experiment. 
(B) MxA knockdown was compared with ISGylation knockdown and p56 
knockdown experiments. (C)Effects of GBP-1, PLSCR1, and viperin 
knockdown experiments were compared to that of the p56 knockdown 
experiment. 
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2.4 DISCUSSION 
IFN-α/β treatment of human cells induces the synthesis of ISG15 and three of its 
conjugating enzymes, resulting in the conjugation of a large number of proteins (Korant 
et al. 1984; Blomstrom et al. 1986; Haas et al. 1987; Loeb and Haas 1994; Narasimhan et 
al. 1996; Yuan and Krug 2001; Zhao et al. 2004; Dastur et al. 2006; Wong et al. 2006; 
Durfee et al. 2008; Zhao et al. 2005; Pattyn et al. 2008). Experiments using ISG15-
knockout (ISG15-/-) mice established that ISG15 and/or its conjugation inhibits the 
replication of influenza A virus. (Lenschow et al. 2007). In the present study we 
demonstrated that IFN-induced ISG15 conjugation inhibits influenza A virus gene 
expression and replication in human tissue culture cells. By siRNA-mediated depletion of 
the two enzymes that catalyze ISG15 conjugation, we demonstrated that suppression of 
ISG15 conjugation in human cells caused approximately a 10-20-fold reduction in the 
IFN-induced antiviral activity against influenza A virus gene expression and replication. 
Based on the amount of restoration of influenza A virus gene expression by these 
ISGylation pathway-specific siRNAs, we estimated that ISG15 conjugation comprises 
approximately 15% of the IFN-induced antiviral activity against influenza A virus in 
human cells. Free ISG15 does not contribute to this antiviral activity against influenza A 
virus because the siRNA knockdowns had little or no effect on the level of free ISG15, 
but these experiments do not rule out the possibility that free ISG15 may have additional 
antiviral activity against influenza A virus in human cells. Our results establish that 
ISG15 modification of target proteins inhibits influenza A virus gene expression and 
replication in human tissue culture cells. In contrast, a significant effect of ISG15 and/or 
its conjugation on influenza A virus infection has not been detected in at least one mouse 
cell line, specifically MEFs. A previous study reported there was no significant difference 
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in influenza A virus replication between ISG15+/+ and ISG15-/- MEFs (Lenschow et al. 
2007). We confirmed these results, and also found that pretreatment of these MEFs with 
mouse IFN-β to induce efficient ISG15 conjugation resulted in the same extremely 
efficient inhibition of influenza A viral gene expression in both ISG15+/+ and ISG15-/- 
MEFs. These results suggest that there are important differences between the mouse and 
human ISG15 conjugation systems with regard to their antiviral activities against 
influenza A virus. In fact, it is already known that human ISG15 shares only 66.7% 
homology with mouse ISG15.  
Recent studies indicated that ISG15 has antiviral activities against other viruses. 
In the case of HIV-1 and Ebola virus, the antiviral function is most likely mediated by 
free ISG15 alone, which suppresses the ubiquitination of viral proteins that is required for 
efficient virus release (Malakhova and Zhang 2008; Okumura et al. 2006). In contrast, a 
study of the effect of ISG15 on Sindbis virus replication provided initial evidence that 
ISG15 conjugation may be responsible for antiviral activity (Lenschow et al. 2005).  
Specifically, the C-terminal LRLRGG motif of ISG15, which is required for conjugation, 
is also required for antiviral activity against Sindbis virus. Here we provide direct 
evidence that ISG15 modification of target proteins inhibits influenza A virus gene 
expression and replication in human tissue culture cells. ISG15 conjugation could exert 
its antiviral activity against influenza A virus by two mechanisms that may not be 
mutually exclusive. In one mechanism, ISG15 conjugation of cellular target proteins, 
e.g., the previously identified antiviral MxA and p56 protein targets, is required for, or at 
least strongly enhances, their antiviral activities. In the second mechanism, ISG15 
conjugation of the viral protein(s) inhibits one or more of its essential functions. Based on 
the present study, human cells in tissue culture should provide tractable systems to 
delineate the mechanisms by which ISG15 conjugation inhibits influenza A virus 
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replication. Our lab is currently investigating possible ISG15 conjugation of influenza 
viral proteins and identifying the conjugation site(s). Once the site(s) is determined, 
recombinant virus expressing mutant protein(s) resisting ISG15 modifications can be 
generated and assayed in human cells by the RNAi approach described in this study to 
determine the functional relevance of such ISG15 conjugation on viral proteins. If the 
ISG15 conjugation of the viral protein inhibits its functions, the mutant viruses without 
the conjugation site could escape from the ISG15 antiviral effects, thus showing better 
replication after IFN pretreatment and less sensitivity to ISG15 siRNA knockdown. 
Recent studies have identified there are at least two ISG15 E3 enzymes, namely 
Herc5 and Efp. Interestingly, the two enzymes have different target specificity: Efp only 
targets 14-3-3 protein, while Herc5 can function on all the targets assayed in co-
transfection experiments. In our future study, we will also use the RNAi protocol to 
examine the role of Efp and Herc5 in the antiviral activity of ISG15 conjugation, which 
could help us to clarify that which of these ISG15 conjugation targets is important for its 
antiviral activity. The siRNA knockdown experiments also demonstrated that three other 
IFN-induced proteins, MxA, p56 and phospholipid scramblase 1, inhibit influenza A 
virus replication in human cells. Our MxA results confirm previous experiments which 
showed that constitutive expression of MxA in the absence of IFN inhibits influenza A 
virus replication (Pavlovic et al. 1992). In contrast, p56 and phospholipid scramblase 1 
had not been shown previously to inhibit influenza A virus replication, although they had 
been shown to inhibit the replication of other RNA viruses (Dong et al. 2004; Zhang et al. 
2007; Wang et al. 2003). Consequently, the present study and those of others have 
demonstrated that the IFN-induced antiviral activity against influenza A virus in human 
cells is mediated at least in part by ISG15 conjugation, MxA, p56, phospholipid 
scramblase 1, and viperin (Pavlovic et al. 1992; Wang et al. 2007; Lenschow et al. 2007). 
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In contrast, the 2’-5’ oligo(A)synthetase/RNase L pathway and PKR do not inhibit 
influenza A virus replication because the viral NS1A protein blocks their inhibitory 
activity (Min and Krug 2006; Min et al. 2007).  
So far, all of the RNAi experiments presented in this study target single antiviral 
protein and result in only partial relief from IFN inhibitory effects. In the future, the 
combination of siRNAs target different potential antiviral proteins will be employed in 
search of the maximal synergetic effects. Such investigation could provide further 
insights into the mechanistic aspects about the action of individual antiviral protein, 
especially the possible crosstalk between these molecules. In this respect, it would be of 
special interest to determine whether knocking down ISG15 and its target proteins 
together would promote further influenza viral gene expression than single ISGylation 
knockdown experiment. 
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Chapter 3 : Identify NS1A interacting proteins during viral infection 
in vivo 
 
3.1 INTRODUCTION 
The non-structural NS1 protein of influenza A virus (NS1A) is an important 
multifunctional virulence factor (Horimoto and Kawaoka 2005; Noah and Robert M. 
Krug 2005); it counteracts host cell antiviral defenses by engaging in multiple protein-
RNA and protein-protein interactions (Krug et al. 2003). NS1A protein is composed of 
two domains: the N-terminal 73 amino acids comprise the RNA-binding domain which 
forms a symmetric homodimer with a unique six-helical chain fold (Liu et al. 1997; 
Chien et al. 1997; Yin et al. 2007); the remaining amino acids constitute the effector 
domain. The RNA-binding domain binds dsRNA with low affinity, but is functionally 
implicated in protecting influenza A virus against the antiviral state induced by IFN-β 
through inhibiting the IFN-α/β-induced 2'-5'-oligo (A) synthetase (OAS)/RNase L 
pathway (Min and Krug, 2006). The effector domain fulfilled multiple biological 
functions by binding to an array of the cellular proteins: (i) the inhibition of the 3’- end 
processing machinery by binding to the 30-kDa subunit of the cellular cleavage and 
polyadenylation specificity factor (CPSF30) and poly(A)-binding protein II (PABII) 
(Nemeroff et al. 1998; Chen et al. 1999; Li et al. 2001; Noah et al. 2003; Twu et al. 2006; 
); (ii) inhibition of the activation of dsRNA-activated protein kinase (PKR)by directing 
binding to PKR(Li et al. 2006; Min et al. 2007); and (iii) the activation of 
phosphatidylinositol-3-kinase (PI3K) signaling by binding to p85β subunit of PI3K (Hale 
et al. 2006; Shin et al. 2007a; Ehrhardt et al. 2007). In addition, one of the most recent 
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study found that NS1A from avian strains, but not from human strains, interacts with 
CrkL/CrkL in virus-infected cells (Heikkinen et al. 2008). The biological relevance of 
this strain-specific interaction is still unknown. It is also suggested that NS1A interacts 
with other influenza viral proteins, e.g. NP and influenza viral polymerases, in viral 
infected cells (Marion et al. 1997). However, the direct binding between NS1A and NP or 
polymerases could not be established in vitro and further study is required to fully 
understand how these interactions occur during virus infection.  
Besides the above NS1A interactions with verified significances in the context of 
viral infection, there were also a number of other cellular proteins identified previously as 
NS1A interactors. These proteins include NS1-I (Wolff et al. 1996), NS1-BP (Wolff, et 
al. 1998), hStaufen (Falcon et al. 1999), eukaryotic translation initiation factor 4GI 
(eIF4GI) (Aragon et al. 2000), poly(A) binding protein I (PABP1) (Burgui et al. 2003), 
retinoic acid-inducible gene I product (RIG-I) (Mibayashi et al. 2007), mRNA export 
machinery (Satterly et al. 2007), and importins (Melen et al. 2007). Although some of 
these interactions show biological effect in artificial context, e.g. transient co-transfection 
assay, they lack supporting evidences from direct study of interactions in viral infected 
cells.   
One of the major reasons accounting for that most of previously identified NS1A 
interacting proteins have not shown biological relevance is the intrinsic limitation in the 
methods employed for their identification.  There have been two major methods in 
previous search of NS1A interactors: (i) yeast two hybrid screening (ii) co-
immunoprecipitation approach. Although these methods are widely used to study protein-
protein interactions, they have important disadvantages. With yeast two-hybrid screening, 
the disadvantage is that the result largely depends on the quality of library used for 
screening, and it also has limitation in detecting interactions of a protein complex where 
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strong association is assembled by weak individual protein interactions. For the co-
immunoprecipitation approach, anti-serum was used for pulling down NS1A protein from 
lysates derived from cells where NS1A was either expressed by transfection (most of the 
cases) or by infection with wild type influenza A virus. The efficiency and specificity of 
the antibodies greatly affects the outcome. In addition, if specific NS1A-mediated protein 
interactions, e.g. interaction between NS1A and viral polymerase as discussed further 
below, are only present in infected cells, these interactions will not be detected by 
expression of NS1A alone as in the transfection approach. These setbacks restrict 
previous study to identify the actual catalogue of NS1A interactions during viral 
infection. To overcome the drawbacks associated with previous approaches studying 
NS1A-mediated protein interactions, in the present study, we set out to generate a 
recombinant influenza A virus encoding epitope tagged NS1A protein, which can be used 
for specific and efficient proteomic analysis in identifying NS1A associated proteins 
during viral infection.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Cell lines 
A549 human lung carcinoma cells, Madin–Darby canine kidney (MDCK), and 
293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM)(GIBCO®) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS)(GIBCO®), 2 mM l-
glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin(GIBCO®) at 37°C under 
a 5% CO2/95% air atmosphere. Anti-Py antibody-secreting AK6967 hybridoma cells, 
provided by Dr, Scott Stevens, were maintained in Dulbecco's modified Eagle's medium 
(DMEM)(GIBCO®) supplemented with 10% heat-inactivated fetal bovine serum 
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(FBS)(GIBCO®), 2 mM l-glutamine, 100 units/ml penicillin, and 100 μg/ml 
streptomycin(GIBCO®) at 37°C under a 5% CO2/95% air atmosphere as suspended cells 
in flasks. To harvest antibodies, hybridoma cells were transferred into Protein-free 
Hybridoma Medium (PFHM) (GIBCO®) without antibiotics or supplements and grown 
until 3 days past confluence. Cell debris was removed by centrifugation. Supernatant 
containing antibodies was filtered and saved at -20°C with 0.02% sodium azide. 
 
3.2.2 Generating N-terminal tagged influenza A/Udorn/72 virus 
pHH21 plasmids containing the full-length cDNAs for each of the eight influenza 
A/Udorn/72 genomic RNA segments, and four pcDNA plasmids expressing NP, PA, 
PB1, and PB2 proteins of influenza A/Udorn/72 were provided by Makoto Takeda (Dr. 
Robert A. Lamb’s lab, Northwestern University). Virus was generated by co-transfecting 
293T cells with these 12 plasmids in serum- and antibiotics-free Opti-MEM I medium 
(GIBCO®). At 12h post-transfection, the media was changed to Opti-MEM I 
supplemented with 2.5µg/ml N-acetylated-trypsin (Sigma) and penicillin-streptomycin. 
Seven to eight hours after media change, the 293 T cells were overlaid onto MDCK cells 
for viral amplification. Culture supernatants were collected and used for HA assay to 
determine whether substantial amount of virus particles were produced. Clones of 
infectious recombinant virus were isolated as individual plaques by performing plaque 
assays in MDCK cells. Serial 10-fold dilutions of virus samples were used for infecting a 
monolayer of MDCK cells at 37°C. After 1 hour incubation, inoculum was removed, and 
1% semisolid agarose resuspended in DMEM (GIBCO®) containing 2.5µg/ml N-
acetylated trypsin (Sigma) and antibiotics was overlaid onto the cells. Two to three days 
after infection, individual plaque was picked, and the agarose plug was stored in 1.2 ml 
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DMEM containing 1% BSA at -80°C. The isolated plaque was used to further amplify 
the virus in the allantoic cavity of 10-day-old embryonated chicken eggs (Charles River 
Laboratories) at 34°C. Allantoic fluid was harvested 48 hours after virus inoculation, and 
virus aliquots were stored at -80°C. Virus titer (plaque forming units (PFU) /ml) was 
measured by plaque assays in MDCK cells. Plaques were visualized and counted by 
staining the cells with either crystal violet or naphethelene blue-black. Viral genomic 
RNA was extracted by using QIAamp Viral RNA Mini Kit (Qiagen) and subjected to 
RT-PCR using SuperScript® First-Strand Synthesis system (Invitrogen). The resulting 
cDNAs of viral genomic RNA segments were sequenced for validation. 
To generate epitope-tagged NS proteins, sequence of either 3XFlag tag or 2X 
polyoma (Py) tag was inserted between 5’UTR and coding sequence of NS gene in 
pHH21 plasmid. For 2XPy tag, two rounds of PCR reactions were used to insert the 42-
nucleotides (2X MEYMPME) into the NS gene. For 3X Flag tag, the entire 69-
nucleotides sequence of the tag (MDYKDHDGDYKDHDIDYKDDDDK) was cloned 
from p3XFlag-CMV10 expression vector (Sigma), and then fused with NS gene by two 
rounds of PCR. The resulting PCR products containing specific tags with Esp3I sites at 
both ends, were digested by restriction enzyme, and inserted into pHH21 plasmids. The 
pHH21-NS plasmids containing epitope tags were sequenced and used in the co-
transfecting experiment to produce recombinant viruses as previously described. Viral 
genomic RNAs of egg-derived recombinant viruses were extracted and reverse-
transcribed. cDNAs of these vRNAs were amplified and sequenced for validation of 
proper introduction of the epitope tag sequences. 
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3.2.3 Virus and infection 
Wild-type Influenza A/Udorn/72 virus encoding either N-terminal 3XFlag or 
2XPy tagged NS proteins was referred to as 3Fwt or 2Pwt virus, respectively. For affinity 
purification, A549 cells were seeded onto 150mm plates and used for infection when 
cells reached 95-100% confluency. Cells were washed twice with PBS and then either 
infected with non-tagged wt or tagged virus (3Fwt or 2Pwt) at a multiplicity of 5 pfu per 
cell. One hour after adsorption in serum-free DMEM (GIBCO®) at 37°C, virus inoculum 
was replaced by DMEM supplemented with 2% heat-inactivated FBS (GIBCO®) and 
penicillin-streptomycin (GIBCO®), and incubated at 37°C /5%CO2 for additional 7 hours 
before harvesting cell lysates. For multiple cycle growth curve, confluent monolayer of 
MDCK cells were washed twice with PBS, and influenza viruses were diluted with 
serum-free DMEM and added to the washed cells for virus adsorption at a multiplicity of 
infection (MOI) of 0.001 pfu/cell. After incubated at 37°C for 1h, virus inoculum was 
replaced by serum-free DMEM supplemented with 2.5µg/ml N-acetylated trypsin 
(Sigma) and penicillin-streptomycin. Supernatants from culture media containing 
released virus particles were collected every 12 hours for 60 hours, and virus titers were 
measured by performing plaque assays in MDCK cells. All experiments were done in 
triplicates, and virus titers were averaged and used to plot growth curve in logarithmic 
scale. 
3.2.4 Affinity purification 
Eight hours post-infection, A549 cells were lysed in Tris-buffered Saline (TBS; 
50mM Tris-Cl, pH 8.0, 150mM NaCl) plus 1% NP-40 supplemented with Complete® 
protease inhibitor (Roche) and PhoSTOP® phosphatase inhibitor (Roche). After 
incubating on ice for 15 minutes, cell lysate was obtained by removing insoluble debris 
by centrifugation at 14,000rpm for 30 minutes at 4°C. Protein concentration was 
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measured by Bradford assay. Equal amount of protein from each sample was used for 
affinity purification. Anti-Flag M2 agarose (Sigma) was used for anti-3XFlag protein 
purification. For anti-Py affinity purification, anti-Py antibodies harvested from 
hybridoma cell culture supernatant were either coupled onto protein-G sepharose beads 
by dimethyl pimelimidate cross-linking, or used with protein-G sepharose as direct co-
immunoprecipitation without chemical crosslinking  Affinity matrices were washed 
twice with ice-cold PBS and equilibrated with lysis buffer. Cell lysate was then added to 
the washed beads and incubated overnight at 4°C for optimal binding. After binding, 
beads were washed extensively for six times with lysis buffer. For anti-Py purification, 
the last three washes were performed with modified Buffer D250 (20mM HEPES, pH 
7.9, 250mM NaCl, 10mM β-mercaptoethanol, and 8% glycerol). The affinity matrix was 
equilibrated with elution buffer without peptide after wash. Elution was carried out using  
1:1 (v/v) ratio of agarose and 500ng/µl peptide in elution buffer (for anti-3XFlag 
purification, 50mM Tris-Cl, pH7.5, 150mM NaCl, 0.012% Triton X-100, 10% glycerol, 
and 0.2mM EDTA; for anti-Py purification, Buffer D250 ). 3XFlag peptide was 
purchased from Sigma; Py peptide (EYMPME) was synthesized by Invitrogen.  Eluates 
were concentrated by Microcon YM-10 (Millipore). Purified proteins were separated by 
12% SDS-PAGE and visualized by either silver stain (Invitrogen) or colloidal blue 
staining (Invitrogen) according to manufacturer’s protocols.  
3.2.5 Immunoblots 
Proteins were resolved on 12% SDS-PAGE gel, and transferred onto 
nitrocellulose membrane (Bio-Rad) by semi-dry transfer method at 0.8mA/cm2. 
Membrane containing transferred proteins was blocked in 5% milk in TBST at room 
temperature for 1h and preceded to western blot analysis. Either rabbit anti-GST-NS1A 
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or mouse anti-Flag M2 antibodies were used as primary antibody. For rabbit anti-GST-
NS1A antibody, it was used at 1:2000 dilution in 5% milk/TBST. To detect 3XFlag-
tagged protein, mouse anti-Flag M2 antibody (Sigma) was used at 1:1000 dilution in 
5%milk/TBST. Secondary antibody of donkey anti-rabbit HRP was purchase from GE 
Amersham. Rabbit anti-mouse-HRP secondary antibody was purchased from Santa Cruz. 
Both secondary antibodies were used at 1:10000 dilution in 5%milk/TBST. Signal was 
detected by incubating the membrane with Enhanced Chemiluminescent (ECL) western 
blotting substrate (Pierce) and exposed to CL-Xposure film (Pierce). 
 
3.2.6 Immunofluorescence 
A549 cells were seeded onto 4-well chamber slide. While reaching 50% 
confluency, cells were infected with either wild-type or 3XFlag-tagged influenza A virus 
at MOI of 5 pfu/cell. After 1h adsorption, virus inoculum was replaced by DMEM 
supplemented with 2% FBS and penicillin-streptomycin. Six hours post-infection, cells 
were rinsed with ice-cold PBS and fixed by 4% paraformaldehyde in PBS for 20 minutes 
at room temperature. Cells were permeabilized with 0.5% Triton X-100, and blocked 
with 5% normal goat serum in PBS/0.2% gelatin/ 0.1% Tween-20. Cells were then 
incubated with rabbit anti-GST-NS1A antibody diluted 1:200 in blocking buffer for 1 
hour at room-temperature and washed four times with PBS plus 0.1% Tween-20 (PBST), 
and incubated with Fluorescein isothiocyanate-conjugated (FITC) AffiniPure Goat Anti-
Rabbit IgG (Jackson Lab) diluted 1:100 in blocking buffer for 1h at room temperature. 
After washed 3 times with PBST and one time with PBS, the intracellular localization of 
NS1A protein was visualized by using fluorescence microscope. 
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3.3  RESULTS 
3.3.1 A recombinant influenza A/Udorn/72 virus containing N-terminal tag NS gene 
is viable and not attenuated. 
The initial purpose of creating influenza A virus with tagged NS1A is to study the 
protein-protein interaction of NS1A with cellular protein during viral infection. Until 
now, most NS1A-protein interactions were identified based on the in vitro pulled down 
experiments. However, although some interacting proteins can be readily pulled down in 
vitro, their biological significance was still not clear when the binding mutants were 
generated, and the interaction did not necessarily reflect the actual events occurring in 
infected cells. Nevertheless, sometimes when antibodies against specific proteins were 
used in co-immunoprecipitation experiments to identify the interaction, the non-specific 
cross-reactivity of the antibodies to other cellular proteins might complicate the 
interpretation of the existence for direct-binding. Also, while antiserum was used, if the 
binding sites were pre-occupied by interacting proteins, some interactions might not be 
detected in the immunoprecipitation results. Therefore, we decided to create influenza A 
virus containing epitope-tagged NS1A protein, in which the NS1A can be specifically 
immunoprecipitated against the epitope without interfering with the protein itself. The 
virus would also be useful to track down the intracellular events during viral infection 
with its epitope tag.  
The influenza NS gene encodes two proteins: NS1, and the spliced form, 
NS2/NEP (Lamb and Choppin 1979; Lamb and Lai 1980). It would be ideal if only 
NS1A is tagged with the epitope. However, when the tag was introduced at the 3’end of 
NS1A ORF, it is inevitable that the NS2 structure will be affected (Figure 3.1(A)).  
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Figure 3.1 NS gene of Influenza A virus. (A)NS gene of influenza A virus encodes 
two proteins, NS1A and NS2A. Alternative splicing of NS mRNA which 
leads to the production of NS2A protein was shown. (B) Schematic diagram 
of creating N-terminal epitope-tagged NS construct. 
 
(A) 
(B) 
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Figure 3.2 Schematic diagram of the strategy of generating recombinant influenza 
A/Udorn/72 viruses by 12-plasmid co-transfection system. Adapted from 
Neumann and Kawaoka 2001. 
 
Driven by RNA pol II promoter 
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As a result, recombinant virus encoding C-terminal tagged NS1A was not viable. 
The 69 nucleotides encoding 3XFlag tag or 42 nucleotides encoding 2XPy tag were 
inserted into NS gene between 5’UTR and start codon of NS open reading frame (Figure 
3.1(B)).The resulting DNA was cloned into pHH21 vector to express viral genomic RNA 
with the tag. The pHH21 construct was then used in creating the recombinant virus in the 
12-plasmid transfection system (Figure 3.2).  
Both wild-type and tagged viruses were detected in the culture supernatant 5 days 
after transfection. The virus was further amplified in eggs. Sequencing results confirmed 
that the tag sequence was included correctly in the NS genomic RNA. The tagged 
recombinant viruses formed plaques with size the same as wild type in MDCK cells 
(Figure 3.3(A)), indicating that this virus, which containing N-terminal epitope-tagged 
NS proteins, is viable and does not have substantial defects compared to wild-type 
viruses.  
To confirm that the tagged NS1A protein is expressed at comparable level as non-
tagged wild type virus during viral infection, we infected MDCK cells with both wild-
type and 3XFlag-tagged influenza A virus at MOI of 5 pfu/cell, and harvested cell lysates 
6 hours post-infection. NS proteins were detected on immunoblots with anti-GST-NS1A 
or anti-3XFlag antibodies. As shown in Figure 3.3(B), both wild-type and tagged viruses 
expressed NS1A about the same level. Notably, when anti-Flag antibody was used, 
NS2A protein was detected in 3XFlag-tagged virus infected cell lysate. 
To determine whether the tagged virus has the same growth kinetics compared to 
non-tagged virus, multiple cycle growth curve in MDCK cells was performed to measure 
the rate of replication, using a multiplicity of infection at 0.001 plaque-forming units per 
cell (pfu/cell). The amount of virus produced at each time point was determined by 
plaque assays in MDCK cells (Figure 3.4). 
 77
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 The Influenza A/Udorn/72 virus encoding N-terminal epitope tagged NS 
proteins is not attenuated. (A) Plaques size comparison of wild-type and 
N-3XFlag NS viruses in MDCK cells. (B)MDCK cells were mock-infected 
or infected with either wild-type (wt) virus or virus encoding N-terminal 
3XFlag tagged NS proteins (NFN). Expression of NS proteins in infected 
cells was analyzed by western blot. 3XFlag tagged NS1A was detected by 
either α-GST-NS1 or α-3XFlag antibodies. Non-tagged NS1A was only 
detected by α-GST-NS1 antibody. NS2A protein was also identified when 
α-3XFlag antibody was used. 
(A) 
(B) 
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Figure 3.4  Influenza A/Udorn/72 viruses encoding N-terminal 3XFlag tagged NS 
proteins (NFN) have the same growth kinetics and nuclear localization 
as non-tagged wild type viruses. (a) Multiple cycle growth curve of non-
tagged wild-type and N-3Xflag-NS influenza A/Udorn/72 viruses. MDCK 
cells were infected at a MOI of 0.001 pfu/cell. Virus production was 
measured by plaque assays in MDCK cells. (b) Immunofluorescence 
analysis of the intracellular localization of NS proteins. A549 cells were 
infected at MOI of 5 pfu /cell. NS proteins were detected by using α-GST-
NS1 as primary antibodies for immunofluorescence analysis. 
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As shown in Figure 3.4(A), both tagged and non-tagged viruses grew at the same 
rate. Immunofluorescence was carried out to confirm that 3XFlag tagged NS1A also 
localized in the nucleus as seen in non-tagged wild-type (Figure 3.4(B)). These results 
indicated N-terminal tagged NS proteins do not interfere with their normal functions, and 
the tagged viruses behave the same as non-tagged wild-type viruses. 
 
3.3.2 Affinity purification of proteins associated with 3XFlag or 2XPy tagged NS 
proteins 
To pull down NS1/NS2 associated proteins during viral infection, human lung 
carcinoma A549 cells were infected with influenza A/Udorn/72 viruses encoding either 
non-tagged or epitope-tagged (3XFlag or 2XPy) NS proteins, at a multiplicity of 
infection of 5 pfu/cell for 6 hours. Cell lysates were prepared in 1%NP-40 lysis buffer 
and run through 25 3/8G needle several times. Same amount of total protein from each 
sample was used for affinity purification. For 3XFlag tagged NS proteins, anti-Flag M2 
agarose(Sigma) was used for the purification. For 2XPy tagged NS proteins, two methods 
were employed to achieve the purpose. Cell culture supernatant of hybridoma cells 
secreting anti-polyoma (Py) antibodies were collected and incubated with protein-G 
sepharose beads. These beads were either chemically crosslinked to create affinity 
column by coupling the antibodies onto beads or were used directly for immuno-
precipitation of Py-tagged NS proteins. Significant amount of tagged NS1A proteins was 
decreased from the input after binding, as shown in Figure 3.5. 
 
After binding, affinity matrices were extensively washed by lysis buffer. Tagged 
NS proteins and their associated proteins were specifically eluted by 3XFlag or 2XPy 
peptides.  
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Figure 3.5 N-terminal tagged NS1 can be efficiently pulled down from infected cell 
lysate. A549 cells were infected by wild-type (wt) virus or viruses encoding 
N-terminal tagged NS proteins: (A) 3XFlag tagged (3F) and (B) 2XPy 
tagged (2P). After 6 h infection, cell lysates were harvested and followed by 
affinity purification against specific tags. For 2P viruses, either cross-linked 
Py column (anti-Py column) or direct immunoprecipitation (anti-Py IP) were 
used. Bound proteins were eluted by using specific peptide, 3XFlag peptide 
or 2XPy peptide. Cell lysates before (Input) and after binding (unbound) to 
the affinity matrices and eluates were analyzed by western blot using 
antibody against NS1A protein. 
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Figure 3.6 Affinity-purified NS1A and interacting proteins were separated by 10% 
SDS-PAGE. Peptide eluates from affinity purification were resolved on 
10% SDS-PAGE. (A) Silver stain; (B) Colloidal Blue stain. wt: wild-type; 
3F: 3XFlag; 2P:2XPy. Position of NS1A proteins were marked as indicated. 
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Elution was carried out several times with small quantities of concentrated peptides. The 
eluates were resolved on 12% SDS-PAGE gel, and analyzed by western blot, silver stain, 
or colloidal blue stain as shown in Figure 3.5 and Figure 3.6.  
As expected, tagged NS proteins bound to the affinity matrices, and after peptide 
elution, could be detected with their associated proteins on stained gel. When analyzed by 
western blot using α-GST-NS1A antibody, signal could only be detected with eluates 
containing tagged proteins. Non-tagged NS proteins did not bind to the affinity matrix, 
thus only several background protein bands appeared on the stained gel, and no signal 
was detected in western blot analysis. This result indicated that influenza A virus with 
tagged NS gene can be readily used for proteomic study to specifically pull-down protein 
complexes associated with NS proteins during viral infection, which allows further study 
of the biological significance of the interactions in vivo. 
3.4  DISCUSSION 
The initial objective of this project is to generate recombinant influenza 
A/Udorn/72 viruses encoding epitope-tagged NS1A in order to identify its associated 
proteins during viral infection. In this study, we generate two viruses in which NS1A and 
NS2A proteins are tagged with either 3XFlag or 2XPy epitope. These two tagged viruses 
are not attenuated in terms of plaque size or virus replication when compared to the wild-
type virus. In addition, the majority of these tagged NS1A proteins, like wild type non-
tagged NS1A protein, localize in the nucleus in infected cells. These data collectively 
demonstrate that the N-terminal epitope tagging does not affect NS1A functions. The 
advantage of using epitope–tagged bait proteins for identifying their interactors is that 
they can be readily purified via strong binding to the affinity matrices followed by 
selective elution with competitive peptide. This approach largely solves the problems 
 83
associated with using protein-specific antiserum for direct co-immunoprecipitation, 
including ineffective antigen-antibody binding and immunoglobin contamination in 
immunoprecipitates eluted by directly boiling in SDS-sample buffer. Indeed, the results 
shown in this chapter indicate that the viruses expressing tagged NS1 proteins can be 
used to effectively purify NS proteins-containing protein complex from infected cells.  
However, a new obstacle was encountered during the application of this novel 
approach, that is, the unwanted tagging of other viral protein. The NS gene produces not 
only NS1A protein, but also NS2A protein as a result of alternative splicing. These two 
proteins share the same 10 amino acids at the very N-terminus, as well as the N-terminal 
epitope in the tagged virus that we generated.  
In order to tag only NS1A protein, we should target its C-terminus. However, as 
discussed earlier, such tagging would greatly alter NS2A coding sequence. NS2A is 
important for nuclear export of newly synthesized viral proteins and essential for viral 
replication. Thus, attempts of tagging the C-terminus of NS1A protein were not 
successful, as no viable virus particles could be recovered from the reverse genetics 
system. Furthermore, even that such virus can be obtained, it could be much attenuated, 
and the protein interactions present in these virus-infected cells may not resemble those 
in wild type non-tagged counterparts. For the same reason, internal tagging of NS1A 
protein would not be suitable, especially since the structure of the intact NS1A protein is 
still unknown. Therefore, the N-terminal tagging strategy was employed. Since the N-
terminal tag will target both NS1A and NS2A proteins, the purified protein complex will 
contain both NS1A and NS2A interacting proteins as shown in Figure 3.7.  
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Figure 3.7 NS2A protein is co-purified with NS1A and other interactors. A549 cells 
were infected with either wild-type of N-terminal 3XFlag tagged NS 
viruses. Peptide eluates after affinity purification were resolved on 12% 
SDS-PAGE. As indicated, NS1A and NS2A were co-purified in the eluates. 
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Theoretically, it is still possible to use the virus encoding N-terminal tagged NS 
proteins to identify NS1A associated factors as proteins identified by mass spectrometry 
analysis can be validated for its NS1A binding specificity using in vitro interaction assay.  
However, the two-step approach will be time-consuming and lose the advantage the 
tagging virus strategy provides. Thus, our effort to purify NS1A-specific associated 
factors had been focusing on the depletion of NS2A from either the lysate or eluates. Two 
attempts with different strategies were made to achieve this goal: using anti-NS2A serum 
or including a second different tag on the C-terminus of NS2A protein. As discussed 
earlier, the drawback of using antiserum is that sometimes it would not provide efficient 
binding. Two problems had surfaced while using NS2A antiserum-based approach. The 
NS2A antiserum that we tested could only pull-down a portion of NS2A protein when 
incubating for several hours as in regular co-immunoprecipitation experiments. When the 
incubation was prolonged to achieve more efficient NS2A depletion, NS1A was non-
specifically pulled down, possibly because the polyclonal antibodies recognize the N-
terminus shared by NS1A and NS2A. 
The other approach involves the attachment of another epitope tag at the C-
terminus of NS2A that differs from the one already presents at the N-terminus of both 
NS1A and NS2A proteins. Thus, the double-tagged NS2A could be separated from 
single-tagged NS1A by affinity purification based on the second tag specific to NS2A 
(Figure 3.8). However, viruses encoding either N-3XFlag-C-2XPy-NS2A or N-2XPy-C-
3XFlag-NS2A protein could not be recovered from reverse genetic system. Each genomic 
RNA segment of influenza A virus contains specific packaging signal encompassing both 
5’- and 3’-UTRs and parts of coding sequences. The introduction of two tags on both 
ends of NS gene may lead to the disruption of packaging signal and, as a result, NS gene 
segment cannot be effectively incorporated into the virion. 
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Figure 3.8 Schematic diagram of creating double-tagged NS2A construct.  A 
second epitope tag different from the N-terminal tag was attached to the C-
terminus of NS2A protein. As a result, pHH21 vectors containing either N-
3XFlag-C-2XPy-NS gene or N-2XPy-C-3XFlag NS gene were generated. 
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Despite the obstacles listed above, these tagged viruses might still show their 
worth in elucidating NS1A functions. As described in the introduction, one of the most 
important NS1A functions is to bind the CPSF 30kD subunit (CPSF30) and thus blocks 
the maturation of host messenger RNA, including IFN-β mRNA. Our most recent study 
suggested the existence of a macromolecular complex in infected cells that contains 
CPSF30, NS1A, and viral polymerases, implicating there might be more profound 
function of CPSF30-NS1A interaction. In brief, transiently expressed GST-CPSF30 in 
infected cells can pull down not only NS1A but also viral polymerases and NP protein. 
To gain further insight into the actual function of this macromolecular complex, it is 
important to identify its components, and the tagged virus is extremely useful for this 
purpose. We will use the double purification strategy to isolate the macromolecular 
complex anchored on CPSF30 and NS1A: GST-CPSF30 expression vector will be 
transiently transfected into 293T cells which will then be infected with the recombinant 
viruses encoding tagged NS proteins. It is worth noting that, since GST-CPSF30 only 
binds to NS1A but not to NS2A, the first purification will eliminate the NS2A 
interference that has been the major concern for using these tagged viruses. GST-
CPSF30-NS1A complex will be first isolated by GST purification and glutathione 
elution. The eluate will be subjected to the second affinity purification based on the 
specific epitope tag on NS1A protein. This double purification approach should result in 
high-purity isolation of NS1A-CPSF30 complex from infected cells, and we would then 
first determine whether the viral polymerases are indeed the integral part of this complex. 
Although this experiment will not provide answers to the complete listing of all the 
NS1A associated proteins in infected cells, since it is limited in only identifying NS1A 
binding partners in NS1A-CPSF30 complex, it is essential for studying the possible 
interaction of NS1A with viral polymerases and NP during viral infection. In addition to 
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viral proteins, host factors, if any, in this macromolecular protein complex will also be 
specifically identified by the double purification. This will facilitate the research of the 
functions for this macromolecular protein complex.  
Finally, although the recombinant influenza A/Udorn/72 virus encoding N-
terminal tagged NS proteins has its limitations in truly identifying NS1A associated 
proteins during viral infection, it was used for identifying the actual phosphorylation sites 
on NS1A protein during viral infection as described in the following chapter.  
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Chapter 4 : NS1A protein of influenza A/Udorn/72 viruses is 
phosphorylated on both Threonine and Serine residues. 
 
4.1 INTRODUCTION 
Phosphorylation is an important post-translational modification that has been 
shown to regulate various biological activities in the cells. Numerous viral proteins have 
been shown to be phosphorylated during viral infection. The phosphorylated proteins in 
influenza A virus include NP (Privalsky and Penhoet 1977; Skorko et al. 1991; Arrese 
and Portela 1996), NS1(Privalsky and Penhoet 1978; Privalsky and Penhoet 1981; Petri 
et al. 1982), NS2(Richardson and Akkina 1991), PA(Sanz-Ezquerro et al. 1998; Huarte et 
al. 2003), M1(Gregoriades et al. 1984; Reinhardt and Wolff 2000), and M2 (Holsinger et 
al. 1995; Thomas et al. 1998). NS1A phosphorylation was first described 30 years ago 
using a two-dimensional gel electrophoresis analysis (Privalsky and Penhoet 1978). 
Infected cells were pulse-labeled with 32P-orthophosphate, and the phosphorylated 
proteins were examined by two-dimensional gel electrophoresis followed by 
autoradiography. Two phosphorylated species of NS1A proteins were identified, thin-
layer electrophoresis analysis of phosphoamino acids indicated that two threonines (Ts) 
in the NS1A protein were probably phosphorylated (Privalsky and Penhoet 1981). It was 
also suggested that the phosphorylation occurred either after or simultaneously with 
translocation of NS1A into the nucleus. In a later report (Petri et al. 1982), NS1A 
phosphorylation was reported to vary among strains. Among the viruses tested, only NS1 
proteins of human strains are phosphorylated. Ever since then; however, the actual 
phosphorylation sites on NS1A were never identified, and the biological significance of 
NS1A phosphorylation was not addressed. In the present study, we identify the 
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phosphorylation sites of the NS1A protein during viral infection by affinity purification 
using the influenza A/Udorn/72 virus expressing N-terminal tagged NS1A protein, 
followed by mass spectrometry, and demonstrate that one of these phosphorylations, at 
the T at position 215, is critical for virus replication. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Cell lines 
 A549 cells, MDCK cells, , 293T cells, and Hel299 cells were grown in 
Dulbecco's modified Eagle's medium (DMEM) (GIBCO®) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (GIBCO®), 2 mM l-glutamine, 100 units/ml 
penicillin, and 100 μg/ml streptomycin (GIBCO®) at 37°C under a 5% CO2/95% air 
atmosphere. Calu3 cells were grown in Advanced MEM (GIBCO®) supplemented with 
10% heat-inactivated fetal bovine serum (FBS), 2 mM l-glutamine, 100 units/ml 
penicillin, and 100 μg/ml streptomycin at 37°C under a 5% CO2/95% air atmosphere.  
 
4.2.2 Generating recombinant influenza A/Udorn/72 viruses by reverse genetics 
Recombinant influenza A/Udorn/72 viruses were generated as described in 
chapter 2. In brief, 293T cells were co-transfected with pHH21 plasmids containing the 
full-length cDNAs for each of the eight influenza A/Udorn/72 genomic RNA segments, 
and four pcDNA plasmids expressing NP, PA, PB1, and PB2 proteins of influenza 
A/Udorn/72 virus. Transfected 293T cells were subsequently overlaid onto MDCK cells 
for more efficient virus production. Culture supernatants containing recombinant virus 
particles were collected and used for isolating individual plaques by performing plaque 
assays in MDCK cells. Serial 10-fold dilutions of viral samples were used for infecting a 
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monolayer of MDCK cells, and 1% semisolid agarose resuspended in DMEM containing 
2.5µg/ml N-acetylated trypsin (Sigma) and antibiotics was overlaid onto the cells. Two to 
three days after initial infection, individual plaques were picked and stored in 1.2 ml 
DMEM containing 1% BSA at -80°C. The plaque was used to further amplify the virus in 
the allantoic cavity of 10-day-old embryonated chicken eggs (Charles River Laboratories) 
at 34°C. Allantoic fluid was harvested after 48 hours, and virus aliquots were stored at -
80°C. Virus titer was measured by plaque assays in MDCK cells. Plaques were visualized 
by staining with either crystal violet or naphethelene blue-black. Influenza A virus 
encoding N-terminal 3XFlag tagged NS proteins was generated by inserting the 3XFlag 
tag sequence between the start codon and the coding sequence of the NS gene in pHH21 
plasmid used for 12 plasmids co-transfection. Phosphorylation site-specific mutant 
viruses were generated by mutating corresponding sites on NS gene in pHH21 plasmids 
and then used them for co-transfection experiments. Site-specific mutagenesis by PCR 
was performed to create phosphorylation site-specific mutants by changing threonine to 
either alanine or glutamic acid. As a result, recombinant influenza A/Udorn/72 viruses 
encoding NS1A with T49A, T49E, T49Q, T215A, or T215E mutation were generated. 
Viral genomic RNAs of egg-amplified recombinant viruses were extracted and sequenced 
to ensure proper introduction of these mutations. 
  
4.2.3 Virus infection and growth curve analysis  
Wild-type influenza A/Udorn/72 virus encoding N-terminal 3XFlag tagged NS 
proteins is referred to as 3Fwt virus. For affinity purification, A549 cells were seeded 
onto 150mm plates and used for infection when cells reached 95-100% confluency. After 
washing twice with PBS, A549 cells were either mock-infected or infected with 3Fwt 
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viruses at a multiplicity of 5 pfu per cell. After an 1 hr adsorption in serum-free DMEM 
at 37°C, virus inoculum was replaced by DMEM supplemented with 2% heat-inactivated 
FBS and penicillin-stryptomycin. Infected cells were incubated at 37°C/5%CO2 for 
additional 7 hours before harvesting the cell lysates. For multiple cycle growth curve, 
confluent monolayer of MDCK cells was washed twice with PBS. Influenza virus was 
diluted with serum-free DMEM and added to the washed cells for virus adsorption at 
multiplicity of infection (MOI) of 0.001 pfu per cell. After incubation at 37°C for 1h, 
virus inoculum was replaced by serum-free DMEM supplemented with 2.5µg/ml N-
acetylated trypsin (NAT) (Sigma) and penicillin-streptomycin. Supernatants from culture 
medium containing released viral particles were collected every 12 hours for 60 hours, 
and virus titer was measured by performing plaque assays in MDCK cells. For single 
cycle growth curve (SCGC), MDCK cells were infected at MOI of 5 pfu per cell. After 
1h virus adsorption at 37°C, cells were washed twice with PBS to remove unbound viral 
particles before replacing with the infection medium. Supernatants were collected every 2 
hour for 10 hours, and virus production was measured by plaque assays in MDCK cells. 
All experiments were done in triplicates, and virus titers were averaged and used to plot 
growth curve in logarithmic scale.  
 
4.2.4 Affinity purification and Mass Spectrometry 
Eight hours post-infection, mock- or 3Fwt- infected A549 cells were lysed in 
Tris-buffered saline (TBS; 50mM Tris-Cl, pH 8.0, 150mM NaCl) plus 1% NP-40 
supplemented with Complete® protease inhibitor (Roche) and PhoSTOP® phosphatase 
inhibitor (Roche), followed by sonication with increasing output for 1 minute on ice. Cell 
lysate was obtained after removing insoluble debris by centrifugation at 14,000rpm for 30 
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minutes at 4°C. Protein concentration was measured by Bradford assay. Equal amount of 
protein from each sample was used for affinity purification. Anti-Flag M2 agarose 
(Sigma) was washed twice with PBS and equilibrated with lysis buffer. Cell lysate was 
then added to the washed beads and incubated overnight at 4°C for optimal binding. After 
binding, the beads were extensively washed with lysis buffer and equilibrated with a 
buffer containing 50mM Tris-Cl, pH7.5, 150mM NaCl, 0.012% Triton X-100, 10% 
glycerol, 0.2mM EDTA. Elution was then carried out twice using 1:1 (v/v) ratio of M2 
agarose and 1µg/µl 3XFlag peptide (Sigma) in the equilibration buffer. Eluates were 
concentrated using Microcon YM-10 (Millipore). Purified protein was resolved on 12% 
SDS-PAGE and visualized by colloidal blue staining (Invitrogen).The NS1A protein 
band was sent to the Taplin Biological Mass Spectrometry Facility at Harvard Medical 
School for phosphorylation analysis. 
 
4.2.5 Immunofluorescence 
Human embryonic lung fibroblasts Hel299 cells were seeded onto 4-well chamber 
slide. Upon reaching 50% confluency, cells were infected with either wild-type or mutant 
influenza A virus at MOI of 3 pfu/cell. After 1h adsorption, virus inoculum was replaced 
by DMEM supplemented with 2% FBS and penicillin-streptomycin. Six hours post-
infection, cells were rinsed with ice-cold PBS, fixed by 4% paraformaldehyde in PBS for 
20 minutes at room temperature, permeabilized with 0.5% Triton X-100, and blocked 
with 5% normal goat serum in PBS/0.2% gelatin/ 0.1% Tween-20. Cells were then 
incubated with rabbit anti-GST-NS1A antibody diluted  1:200 in blocking buffer for 1 
hour at room-temperature and washed four times with PBS plus 0.1% Tween-20 (PBST). 
Fluorescein isothiocyanate-conjugated (FITC) AffiniPure Goat Anti-Rabbit IgG (Jackson 
 94
Lab) was diluted 1:100 in blocking buffer, and added to the cells for incubation at room 
temperature for 1 hour. After washing 3 times with PBST and one time with PBS, the 
intracellular localization of NS1A protein was visualized using fluorescence microscope. 
 
4.2.6 S35 labeling of cells. 
A549 cells or Calu3 cells were seeded onto 6-well tissue culture plates. Confluent 
monolayer cells were either mock-infected or infected with the indicated influenza 
viruses at a MOI of 5 pfu/cell. At various time points post-infection, cells were washed 
twice with PBS and replenished with 1ml methionine- and cysteine-free DMEM 
(GIBCO®). After incubation at 37°C for 15 minutes to deplete unlabeled methionine and 
cysteine, cells were labeled with 10µl mixture of 35S-L-Methionine and L-Cysteine 
(TRANS35S™, MP Biomedical) at a final concentration of 0.1mCi/ml for 30 minutes. 
Cells were then washed twice with ice-cold PBS, and direct lysis was performed with 
200µl/well 1X Laemmli SDS sample buffer. Aliquots of the samples were resolved by 
12% SDS-PAGE and analyzed by autoradiography.  
 
4.3 RESULTS 
4.3.1 Identify phosphorylation sites on NS1A protein of influenza A/Udorn/72 virus 
using mass spectrometry 
Influenza A/Udorn/72 virus encoding N-terminal 3XFlag tagged NS proteins 
(3Fwt) was generated as described in chapter 3. Previous experiments using this virus to 
identify NS1A/NS2A associated proteins showed that high stringency washes of affinity 
columns yielded preparations of NS1A and NS2A proteins with minimal amounts of 
contaminating proteins. This finding showed that high stringency wash would be useful 
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in preparing a pure fraction of the N-terminal tagged NS1A protein for identification of 
the phosphorylation sites on the NS1A protein. 
A549 cells were either mock-infected, or infected with 3Fwt influenza 
A/Udorn/72 virus. After 8 hours of infection, cell lysate was prepared in 1% NP-40 lysis 
buffer. Because the majority of the NS1A protein is in the nucleus of infected cells, the 
lysate was sonicated to disrupt the nuclear membrane. 3XFlag tagged NS1A and NS2A 
proteins were then purified by binding to the anti-Flag M2 agarose, extensively washed 
with TBS plus 1% Triton X-100, and specifically eluted with concentrated 3XFlag 
peptide. The eluted proteins were resolved on 12%SDS-PAGE, and the polyacrylamide 
gel was stained with colloidal blue (Figure 4.1). The protein band corresponding to the 
NS1A protein was cut out and sent for mass spectrometry analysis.  
Mass spectrometry analysis identified 3 sites on the NS1A protein of influenza 
A/Udorn/72 virus that were phosphorylated during virus infection: S42, T49, and T215. 
The previous biochemical study of the NS1A protein indicated that it was phosphorylated 
only on threonine residues, and at two major sites (Privalsky and Penhoet 1981). Our 
findings of phosphorylation at T215 and T49 probably constitute the two previously 
reported major phosphorylation sites of the NS1A protein. In addition, our finding of 
phosphorylation at S42 is the first evidence that serine residues of NS1A protein are 
phosphorylated during viral infection. 
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Figure 4.1 Affinity purification of N-3XFlag NS1A protein from infected cell 
lysate. A549 cells were mock-infected (M) or infected with influenza 
A/Udorn/72 viruses encoding N-3XFlag NS proteins (3F). After extensive 
wash and peptide elution, purified proteins were separated on 12% SDS-
PAGE. E1 and E2 indicate the first and second elution. * represents the 
position of N-3XFlag-NS1A. 
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4.3.2 Generating influenza A/Udorn/72 viruses encoding NS1A with mutated 
phosphorylation sites 
To examine the function of NS1A threonine phosphorylation on viral replication, 
recombinant mutant influenza A/Udorn/72 viruses encoding NS1A proteins with amino 
acid substitutions at positions 49 and 215 were generated. By employing PCR site 
mutagenesis, threonine residue at position 49 or 215 on NS1A was changed to alanine to 
abolish the phosphorylation; or glutamic acid to mimic constitutively phosphorylated 
state. Resulting DNAs were cloned into pHH21 vectors and used in the 12-plasmids co-
transfection of recombinant system to generate mutant viruses. However, NS2A is a 
spliced form of NS gene product with +1 frameshift ORF of the coding sequence in its C-
terminal exon compared to NS1A. Any change made on NS1A in the overlapping region 
has to be examined carefully so that the NS2A protein is not affected. For T49 mutants, 
the change would not affect NS2A protein; however, for T215 mutants, amino acid 
substitutions in the NS1A protein could affect NS2A coding sequence. In the T215A 
mutant virus, the amino acid sequence of NS2A was not altered. In the T215E mutant 
virus, corresponding sequence in NS2A led to a change of leucine to isoleucine, which 
we considered as a minor alteration and should not affect NS2 function. In fact, as 
described below, this mutant virus is not attenuated. Genome segments of mutant viruses 
were sequenced to ensure proper introduction of the mutated sites. As a result, 
recombinant viruses with NS1A encoding the mutations, T49A, T49E, T49Q, T215A, or 
T215E, were successfully recovered from supernatant of recombinant system and 
amplified in embryonated eggs.  
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4.3.3 Phosphorylation of Thr 49 has negative effect on influenza A/Udorn/72 growth 
Recombinant viruses encoding T49A, T49E, or T49Q NS1A proteins were used 
for plaque assay in MDCK cells. When phosphorylation is abolished by introducing Thr-
to-Ala mutation, no obvious difference of plaque sizes were found when compared to 
wild-type virus. This result would direct us to the conclusion that phosphorylation does 
not have biological significance at position 49. However, to our surprise, mimicking 
constant phosphorylated state at position 49 by changing Thr to Glu attenuates the virus, 
as the mutant virus forms pinpoint plaques on MDCK cells (Figure 4.2). In addition, 
mutant virus with Thr-to-Asn change at position 49, which resembled the size of 
phosphorylated Thr without negative charge, was not attenuated in plaque size.  
To examine the effect of phosphorylation on viral growth, we compared the viral 
replication of T49A and T49E mutants to wild-type virus in both single and multiple 
cycle growth in MDCK cells. For multiple cycle growth curve (Figure 4.3(A)), MDCK 
cells were infected at a multiplicity of infection (MOI) of 0.001 pfu per cell, and the 
amount of virus produced was determined by plaque assays. While the T49A mutant 
virus has almost about the same growth kinetics as wild-type virus, the yield of T49E 
mutant virus was about one log less than the wild-type virus. The reduction of T49E 
mutant virus production was also found in single cycle growth curve when MDCK cells 
were infected at high MOI of 5 pfu per cell (Figure 4.3(B)). 
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Figure 4.2 Mimicking constant phosphorylated state at position 49 causes virus 
attenuation. Recombinant influenza A /Udorn/72 viruses encoding Thr-49 
mutant NS1A proteins were generated. Thr-to-Ala (T49A) abolished T49 
phosphorylation. Thr-to-Asp (T49D) and Thr-to-Glu (T49E) mimicked 
constant phosphorylated state. Thr-to-Gln (T49Q) imitated the size of 
threonine with a phosphate group without charge.  
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Figure 4.3 Comparison of the viral replication of T49 mutant viruses in MDCK 
cells. (A) Multiple cycle growth curve. MDCK cells were infected by wild-
type (wt) or T49 mutant viruses at MOI of 0.001 pfu/cell. Virus production 
was measured by plaque assay in MDCK cells at different time points..(B) 
Single cycle growth curve. MDCK cells were infected with MOI of 5 
pfu/cell.  
(A) 
(B) 
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Immunofluorescence showed that the T49A and T49E mutant NS1A proteins, like 
the wild-type NS1A protein, localized in the nucleus, indicating that the attenuation of 
the T49E virus was not due to mislocalization of the mutant NS1A proteins (Figure 4.4). 
These results suggest that phosphorylation at position 49 plays a role in regulating viral 
growth; however, in a negative aspect.  
T49 is highly conserved in human influenza A viruses. If phosphorylation at 
position 49 had only negative effect on viral growth, one would expect that RNA viruses 
with high mutation rate like influenza viruses would have changed this site. Therefore, 
T49 phosphorylation might possess a later positive effect during viral replication, which 
would not be detected unless phosphorylation was introduced from the beginning as seen 
in T49E mutant. However, one would also expect that the T49A mutant virus would be 
attenuated. It is possible that attenuation of T49A was not observed in MDCK cells 
because of insufficient phosphorylation of T49 in wild-type virus due to insufficient 
levels of the appropriate kinases.  
4.3.4 Phosphorylation of Thr 215 has positive effect on influenza A/Udorn/72 growth 
In contrast, mutation of the T215 site shows a different pattern. Recombinant 
viruses encoding T215A or T215E NS1A proteins were generated as described before. 
These viruses were used for plaque assays on MDCK cells. When phosphorylation is 
abolished by introducing a Thr-to-Ala amino acid substitution, the virus formed smaller 
plaques compared to wild-type virus (Figure 4.5(A)). In contrast, mimicking constant 
phosphorylated state at position 215 by changing Thr to Glu does not lead to attenuation. 
No obvious difference of plaque sizes were found when compared T215E to wild-type 
virus (Figure 4.5(B)). This result indicates that phosphorylation at T215 is important for 
virus replication.  
 102
 
 
 
Figure 4.4 T49 mutant NS1A proteins localized in the nucleus. Hel299 cells were 
infected with wild-type or T49 mutant viruses at MOI of 5 pfu/cell for 6 
hours. Localization of NS1A proteins were visualized by immune-
fluorescence analysis.  
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Figure 4.5 Abolishing phosphorylation at position 215 of NS1A protein causes 
attenuation. Recombinant influenza A /Udorn/72 viruses encoding Thr-215 
mutant NS1A proteins were generated. Plaque assay was performed using 
MDCK cells. Thr-to-Ala (T215A) abolished T215 phosphorylation. Thr-to-
Glu (T215E) mimicked constant phosphorylated state.  (A) Abolishing 
T215 phosphorylation results in smaller plaques for T215A mutant virus  
compared to that of the wild type viral infection. (B) Mimicking constant 
phosphorylation at T215 (T215E) does not cause virus attenuation. (C) 
Immunofluoresence. NS1A protein of mutant viruses located at nucleus as 
seen with wild-type viral infection.  
(A) (B) 
(C) 
 104
Immunofluorescence showed that theT215A and T215E mutant NS1A proteins, 
like the wild-type NS1A protein, are localized in the nucleus, indicating that the 
attenuation of the T215A virus was not due to mislocalization of its NS1A protein 
(Figure 4.5(C)).  
To examine the effect of phosphorylation on viral growth, we compared the rate 
of viral replication of T215A and T215E mutants to wild-type virus in both single and 
multiple cycle growth in MDCK cells. For multiple cycle growth curve, MDCK cells 
were infected at a multiplicity of infection (MOI) of 0.001 pfu per cell, and the amount of 
virus produced was determined by plaque assays. While T215E mutant showed almost 
about the same growth kinetics as wild-type virus, the production of T215A mutant virus 
was about two logs lower than that of the wild-type virus (Figure 4.6(A)). The differences 
of the viral replication were also seen in single cycle growth curve when MDCK cells 
were infected at high MOI of 5 pfu per cell. (Figure 4.6(B)). These results show that 
phosphorylation of T215 plays an important role in the replication of human influenza A 
viruses.  
 
4.3.5 Abolishing phosphorylation at position 215 of the NS1A protein might change 
the overall posttranslational modification of the NS1A protein. 
35S-methionine and cysteine pulse-labeling was performed to compare the 
synthesis of virus-specific proteins in cells infected with the T215 mutants and wild-type 
viruses. Either A549 or Calu3 cells were infected with T215A, T215E or wild-type 
viruses at MOI of 5 pfu/cell. Cells were pulse-labeled every 2 hours post-infection and 
analyzed by 12% SDS-PAGE. At each time-point, the majority of virus-specific proteins, 
including NP, polymerases, and HA, showed no significant difference in protein 
expression level between wild type virus and the two T215 mutant viruses (Figure 4.7).   
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Figure 4.6 Abolishing T215 phosphorylation of NS1A protein causes virus 
attenuation. (A) Multiple cycle growth curve. MDCK cells were infected at 
MOI of 0.001 pfu/cell. Virus production was measured by performing 
plaque assays in MDCK cells. (B) Single cycle growth curve. MDCK cells 
were infected at MOI of 5 pfu/cell.  
(A) 
(B) 
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Figure 4.7 Abolishing T215 phosphorylation at position 215 might change the 
overall posttranslational modification of NS1A protein.  Cells were 
either mock-infected (M) or infected with wild-type (T), T215A (A), or 
T215E(E) influenza A/Udorn/72 viruses at MOI of 5 pfu/cell. 35S pulse-
labeling were carried out at time-points indicated. (A) A549 cells. (B) Calu3 
cells.  
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However, in cells infected with the T215A mutant virus, four newly synthesized 
proteins, in comparison to two in samples from wild type virus and T215E virus-infected 
cells, were observed in the SDS-PAGE gel close to the region where NS1A and M1 
proteins migrate (Figure 4.7). Further Western blot analysis demonstrate that the protein 
with the greatest mobility is the M1 protein, and the other three bands with lower 
mobility are NS1A proteins. The combined level of synthesis of these three NS1A 
species is comparable to that of the single species of the NS1A protein synthesized in 
cells infected by either the T215E mutant or wild-type viruses.  
These mobility shifts of the NS1A proteins in SDS-PAGE are most likely caused 
by an overall change in post-translational modification when phosphorylation at T215 is 
abolished. Decreased mobility of these NS1A protein species suggests that they may have 
acquired other protein modifications, probably phosphorylations, in addition to the T215 
phosphorylation. The introduction of new NS1A post-translational modifications by the 
T215A mutation might be either directly due to the mutation at position 215 exposes the 
normally hidden protein surface for additional modification or indirectly resulted from 
the alteration of interaction of NS1A with cellular proteins.  We hypothesize that these 
changes in the NS1A protein lead to the inhibition of specific NS1A functions, causing 
the attenuation of the T215A virus (see Discussion).  
 
4.3.6 Generating recombinant A/Udorn/72 virus encoding NS1A with Thr-to-Pro 
mutation at position 215 
The identity of the amino acid at position 215 of the NS1A protein discriminates 
human influenza viruses from avian influenza viruses (Finkelstein et al. 2007), as 
threonine at this position is conserved in all human strains, whereas proline is present at 
this position in most avian strains.  It is possible that the phosphorylation of Thr-215 
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confers NS1A function(s) similar to that already exist in avian NS1A with Pro-215. To 
examine this possibility, a recombinant influenza A/Udorn/72 virus encoding T215P 
NS1A protein was generated. Due to the necessary codon change, a single amino acid 
change occurs in the NS2 protein. For this reason, we introduced the Thr-to-Pro mutation 
into the Udorn NS1A protein, but that the amino acid of NS2A is the same as that of 
NS2A of avian influenza A viruses (Leu to Ser) (Figure 4.8(A)). Thr-to-Pro recombinant 
mutant virus was generated as described above. As shown in Figure 4.8(B), the plaque 
size of T215P mutant is the same as that of wild-type virus, indicating that when 
threonine 215 was changed to proline, the virus was not attenuated. This conclusion was 
further confirmed by measurement of viral growth in MDCK cell. No significant 
difference was detected between T215P mutant, T215E mutant and wild-type viruses in 
both single- and multiple- cycle growth analysis (Figure 4.9).   
The 35S pulse-labeling experiments revealed that NS1A protein of the T215P 
mutant does not exhibit the SDS page mobility shift observed for the NS1A protein of the 
T215A mutant (Figure 4.10). We thus conclude that the phosphorylation at Thr-215 in 
human strains can be functionally replaced by proline residue that is specific for avian 
strains. One possible explanation for this functional equivalence is that the 
phosphothreonine at position 215 enables the NS1A protein of human influenza virus 
strains to bind to the same protein partner(s) as avian strains via their Pro-215-containing 
sequence.   
 
 109
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Influenza A virus encoding Thr-to-Pro mutation at position 215 has the 
same phenotype as wild-type virus. (A) Schematic diagram comparing 
T215 regions of NS1A proteins of human and avian influenza viruses.T215P 
NS1A influenza A/Udorn/72 mutant virus was generated with Leu to Ser 
mutation in the corresponding region of NS2A proteins to resemble the 
region of avian strain. (B) Plaque size comparison of wild-type, T215A, 
T215E, and T215P NS1A influenza A/Udorn/72 viruses in MDCK cells. 
  
wt T215A T215E T215P 
(A) 
(B) 
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Figure 4.9 Thr-to-Pro mutation at position 215 of NS1A protein of human 
influenza A/Udorn/72 virus does not affect viral replication.  (A) 
Multiple cycle growth curve. MDCK cells were infected at MOI of 0.001 
pfu/cell. Virus production was measured by plaque assays in MDCK cells. 
(B) Single cycle growth curve. MDCK cells were infected at MOI of 5 
pfu/cell. 
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Figure 4.10 Abolishing phosphorylation at position 215 changes the mobility of 
NS1A protein on 12% SDS-PAGE. A549 cells were either mock-infected 
or infected by wild-type (T), T215A (A), T215E (E), or T215P (P) NS1A 
mutant influenza A/Udorn/72 viruses at MOI of 5 pfu/cell or mock-infected 
(M). 35S pulse-labeling were carried out at time points indicated. (A) 
Labeled infection cell lysates were resolved on 12% SDS-PAGE and 
documented by radioautography. (B) Western blot analysis of radio-labeled 
cell lysates. Blot was first probed with goat anti-udorn antibody to detect 
HA, NP, and M1. The same blot was used subsequently for detecting NS1A 
by using rabbit anti-NS1A antibody.  
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4.4 DISCUSSION  
It has been 30 years since the first report of that the NS1A protein contains 
phosphorylated threonine residues (Privalsky and Penhoet 1981), and the actual sites and 
biological functions of NS1A phosphorylation remained elusive. Here, by developing a 
recombinant influenza A virus with N-terminal epitope-tagged NS gene, we were able to 
purify NS1A protein from infected cell to homogenicity for mass spectrometry analysis 
which identified the sites of the NS1A protein that are phosphorylated during viral 
infection. Specifically, our analysis revealed that NS1A protein is phosphorylated at T49 
and T215. It is likely that these sites comprise the two threonine phosphorylations 
suggested 30 years ago. In addition, we discovered a serine phosphorylation site (at Ser-
42 of NS1A protein that was not detected previously). 
The focus of the present study was on the two threonine phosphorylation sites of 
NS1A protein. In order to study the effects of NS1A phosphorylation on viral replication, 
we generated recombinant mutant viruses targeting the phosphorylation sites, which 
either contain Thr-to-Ala replacement to abolish phosphorylation, or Thr-to-Glu to mimic 
a constitutive phosphorylated state. The comparison of these mutant viruses with wild 
type virus in viral growth demonstrated that the phosphorylation of NS1A protein at 
different threonine residues may impact its function differently: phosphorylation of Thr-
215 position is important to support viral growth, while Thr-49 phosphorylation had 
negative effects on viral replication. 
The behavior of the mutations at Thr-49 was surprising. When phosphorylation 
was abolished by changing Thr to Ala, the mutant virus resembles wild-type viruses. On 
the other hand, when constitutive phosphorylation was mimicked via the Thr-to-Glu 
mutant, the virus is attenuated. A mutant virus encoding NS1A with a change of 
threonine to glutamine (Thr-to-Gln), which mimicked the size of threonine plus a 
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phosphate group without the charge, behaves similar to wild-type virus, indicating the 
attenuation seen in T49E virus results from the charged side chain. The attenuation of 
T49E mutant virus indicates that phosphorylation at this position inhibits virus 
replication. However, if this is the case, we might expect that the Thr-to-Ala mutation 
would enhance virus replication, which was not observed. One explanation for this 
discrepancy would be the kinase that phosphorylates T49 is deficient in MDCK cells, and 
thus NS1A protein of wild-type virus is not efficiently phosphorylated at T49 position. So 
the differences of viral replication between T49A and wild-type influenza viruses are not 
obvious. Concomitantly with searching for the kinase responsible for T49 
phosphorylation, we are currently comparing the growth of T49A mutant virus and wild 
type virus in different cell lines which are commonly used in studying influenza A 
viruses.  
Phosphorylation is arguably one of the most important post-translational 
modifications, and numerous cellular kinases participate in regulating multiple vital 
cellular processes. Inevitably, some of the viral encoded proteins, like many of the 
cellular proteins, undergo phosphorylation as first indicated by their possession of 
consensus site(s) for specific kinase.  Although in some cases the phosphorylations of 
viral proteins do not affect their functions and are not essential, e.g. the phosphorylation 
of M2 protein in influenza A virus (Thomas et al. 1998), most of the time viruses take 
advantage of these modifications to benefit their own replications. 
Thr-49, which is highly conserved among influenza A viruses, is located at the 
end of helix 2 of NS1A RNA binding domain in proximity to the dsRNA-binding groove 
(Figure 4.11). The most reasonable explanation for the attenuation of NS1A T49E mutant 
virus is that the substitution of T49 by negatively charged Glu residue abolishes or 
decreases the dsRNA binding activity of NS1A protein. Consequently, the 2’-5’-OAS  
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Figure 4.11 Schematic diagram of phosphorylation sites on the NS1A RNA-binding 
domain. Phosphorylation sites of NS1A RNA-binding domain, Ser42 and 
Thr49, which are identified by mass spectrometry analysis, are shown as 
indicated on each monomer of the dimeric structure. (A) Top view (B) Front 
view. 
(A) 
(B) 
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pathway is reactivated in cells infected with T49E mutant virus, which is similar to the 
R38A mutant virus (Min and Krug 2006), and it inhibits the viral replication. To validate 
this theory, our future experiment will first measure the dsRNA binding activity of T49E 
NS1A protein in vitro using recombinant proteins.  In parallel, we will compare the 
growth of T49A and T49E mutant viruses in RNase+/+ and RNase L-/- MEFs to 
determine their abilities in inhibition of 2’-5’-OAS activation in vivo. 
If the constitutive phosphorylation of Thr-49 of NS1A protein, as mimicked by 
T49E mutation, negatively regulates viral replication, why does the highly mutable 
influenza A virus still retain the Thr-49 residue?  We propose that the phosphorylation 
of Thr-49 of NS1A protein might play a regulatory role in the process of apoptosis 
induced by influenza viral infection.  Influenza viruses induce apoptosis in various cell 
types both in vivo and in vitro (Schultz-Cherry et al. 2001; Takizawa et al. 1993; 
Hinshaw et al. 1994; Zhirnov et al. 2002; Brydon et al. 2005; Zhirnov and Klenk 2007; 
Lam et al. 2008) and NS1A is identified as one of the viral factors controlling this 
apoptotic process. An interesting notion has emerged from the studies that the regulation 
of NS1A on the apoptosis in infected cells could occur at different stages with different 
outcomes (Weisan Chen et al. 2001; Zhirnov et al. 2002; Bruns et al. 2007). Recently a 
number of studies have reported that NS1A interacts with p85β subunit of PI3K kinase, 
leading to the activation of Akt kinase and the down-stream anti-apoptotic signaling 
pathway (Ehrhardt et al. 2007a; Ehrhardt et al. 2007b; Ehrhardt et al. 2006; Shin et al. 
2007b; Shin et al. 2007a; Hale et al. 2006; Li et al. 2008; Hale et al. 2008; Shin et al. 
2007). This anti-apoptotic cellular status, which is present in the early stage of infection 
as indicated by transient activation of the Akt kinase (Zhirnov and Klenk 2007) may 
provide viruses a window for efficient replication in infected cells. During the late stage 
of infection, when the viral replication is almost complete, pro-apoptotic signals take 
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over, and the cellular status shifts from anti-apoptotic to apoptotic.  This shift is 
important for influenza virus propagation.  Indeed, caspase 3 activation is critical for the 
migration of the viral RNPs from the nucleus to the cytoplasm in the infected cells during 
late infection (Wurzer et al. 2003). Our preliminary data has revealed that this fine-tuned 
balance between anti-apoptotic and pro-apoptotic statuses is deregulated in cells infected 
with T49E mutant viruses. Compared to T49A mutant or wild-type virus, T49E mutant 
virus induces caspase 3 activation at very early stage of infection. This early induction of 
apoptosis in infected cells is probably responsible for the attenuated phenotypes of the 
T49E mutant virus. How does the T49E mutation of NS1A protein lead to early apoptosis 
in infected cells? The answer may lie in the 2’-5’-OAS pathway which is inhibited by 
wild-type NS1A protein during infection. It is known that activation of RNase L by 2’-5’-
OAS leads to release of cytochrome c into the cytosol and caspase activation (Rusch et al. 
2004). Thus, the activation of 2’-5’-OAS pathway in cells infected with NS1A T49E 
mutant may render cells more prone to apoptosis in the early stage of infection.  
Together, the above listed evidences and rationales lead us to hypothesize that the Thr-49 
phosphorylation of NS1A protein occurs at late stage of infection and regulates the 
apoptotic event. The phosphorylation of Thr-49 might disrupt the dsRNA binding activity 
of NS1A protein and relieve the inhibitory effect of NS1A on 2’-5’-OAS. To prove this 
hypothesis, we need to first develop an anti-NS1A antibody specific for phospho-
threonine at position 49, which will enable us to determine the time course of Thr-49 
phoshorylation during infection. In addition, we need to identify the kinase responsible 
for the Thr-49 phosphorylation. Intriguingly, our initial computational analysis by using 
web-based phosphokinase prediction softwares, such as NetPho, indicates that Akt 
kinase, which mediates anti-apoptotic signaling as discussed above, is the best kinase 
candidate for Thr-49 phosphorylation. Thus we will examine the candidacy of Akt kinase 
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using in vitro kinase assay in which both the T49 mutant and wild-type NS1A proteins 
will be used as substrates.   
It is intriguing that T215 is one of the phosphorylation sites identified, because 
this amino acid is a signature for human influenza A virus strains. All human influenza A 
viruses contain threonine at this position in the NS1A protein, whereas avian influenza A 
viruses contain proline at this position. A recent report has shown that by retaining the 
avian P215 signature, the tail regions of NS1A proteins of the 1918 virus and H5N1 
viruses form a SH3-domain, which can bind to Crk/CrkL proteins (Finkelstein et al. 
2007). This result suggested that the sequence surrounding position 215 might be 
important for protein-protein interactions. In present study, elimination of T215 
phosphorylation by replacing Thr with Ala resulted in decreased virus replication in both 
multiple cycle and single cycle growth. In contrast, no attenuation occurred when Thr 
was changed to Glu to mimic constitutive phosphorylation. The latter observation 
indicates that either most of the NS1A proteins are phosphorylated at position 215 during 
infection, or the NS1A protein only need a threshold of T215 phosphorylated species to 
exert the related biological functions. Although the T215A mutant virus is attenuated in 
virus production, the rate of viral protein synthesis in T215A virus-infected cells is 
similar to that in cells infected by the T215E mutant and wild type viruses. However, the 
NS1A protein in T215A virus-infected cells does not migrate as a relatively 
homogeneous species, as is the case for the wild-type and T215E mutant protein, but 
rather migrates as three slower moving species. These protein mobility shifts might be the 
causes underlying the attenuation of virus growth observed.  The homogeneous wild-
type and T215E species corresponds to the NS1A protein containing the S42, T49 and 
T215 phosphorylations. One of the slower migrating NS1A proteins in T215A mutant 
virus infected cells is presumably the NS1A protein lacking phosphorylation at T215. 
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The other 2 species may represent NS1A proteins containing additional post-translational 
modifications besides T49 and S42 phosphorylation. These novel post-translational 
modifications could arise from either the alteration of protein-protein interaction or 
structural changes, which are less likely, associated with the T215A mutation. One of our 
immediate future focuses is to purify all three species of NS1A T215A proteins from 
infected cells using tagged virus approach as described above and identify the post-
translational modification associated with each species by mass spectrometry analysis. 
Such identification may provide first mechanistic insight into how T215A mutation 
compromises the NS1A function during infection. As described above, in order to 
analyze the effect of phosphorylation on modified protein, it is important to identify the 
responsible kinase and this would be one direction for the future study of T215 
phosphorylation. Our initial bioinformatics analysis predicted multiple kinases as 
potential candidates for catalyzing T215 phosphorylation. These candidates include 
Proline-dependent S/T kinase Cdc2 and Cdk5, GSK3, and MAPK. We will first use in 
vitro kinase assay to examine the candidacy of these kinases using both wild type NS1A 
and T215A mutant as substrates. Along with the above future directions, we will take a 
shortcut approach to investigate whether the T215 phosphorylation affects the interaction 
of NS1A and cellular proteins. This approach is inspired by the finding that the 
replacement of T215 with Pro is not attenuating. This substitution makes the C-terminal 
tail of mutated Udorn NS1A protein resemble that of the NS1A proteins of avian origin. 
Avian NS1A proteins with proline at position 215 form a SH3 domain (P-X-X-P), which 
has been reported to bind to the Crk and CrkL proteins (Heikkinen et al. 2008). This 
interaction between NS1A and CrkL appears to enhance PI3K induced Akt signaling, as 
it has been suggested that CrkL functionally interacts with PI3K complex. It is 
conceivable that phosphorylated of T215 in the wild-type human (Ud) NS1A protein 
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provides a novel motif that binds cellular proteins with functions that are similar to those 
bound by the SH3 domain of avian NS1A proteins. Alternatively, phosphorylation of 
T215 may achieve the same function as the avian SH3 domain by a totally different 
mechanism. We are currently starting to investigate this possibility by examining the 
interaction between Crk/CrkL and NS1A proteins from T215E, T215P, T215A mutant or 
wild-type virus infected cell lysates. 
The present study revealed that the attenuation of T215A mutant virus is caused 
by defects after viral protein synthesis, most possibly at one or more steps in process of 
virus particle production. It reminds us a recent study on Hepatitis C virus (HCV) which 
established that the elimination of a serine phosphorylation of HCV NS5A protein 
inhibits virus replication at the step of virus assembly without affecting early RNA 
replication steps. (Tellinghuisen et al. 2008). It is interesting to note that the HCV NS5A 
protein shows striking similarity to the influenza A virus NS1A protein in several other 
respects. Not only is NS5A a RNA-binding protein (Huang et al. 2005), it is also an 
important viral factor in subverting the IFN response in HCV infected cells. NS5A 
interacts with PKR (Gale et al. 1998) and 2’-5’-OAS (Taguchi et al. 2004) to repress 
cellular antiviral activity. It promotes PI3K/Akt anti-apoptotic pathway by interacting 
with the SH3 domain of the PI3K p85 regulatory subunit (Street et al. 2004). NS5A also 
binds viral encoded RNA-dependent RNA polymerase NS5B and modulate its activity 
(Shirota et al. 2002). Thus, the extensively studied phosphorylation of HCV NS5A 
protein may provide a model for the future studies of NS1A phosphorylation of influenza 
A virus. Further studies of the activities and the regulation of these virus-encoded 
multifunctional nonstructural proteins will shed new light on viral pathogenesis and 
ultimately lead to new therapeutics with less side effect and improved efficacy.  
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